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ABSTRACT
Current endovascular stents and synthetic vascular grafts have poor clinical outcomes in small
diameter applications due to high incidence of thrombogenicity and intimal hyperplasia. To address
this, we have developed an albumin film for mitigation of the complications of platelet adhesion and
smooth muscle cell hyperplasia and hypertrophy.
A human serum albumin (HSA) film is fabricated on an anchoring layer of poly (glycidyl
methacrylate) on surfaces of metallic and polymeric substrates. The PGMA and HSA layers are
characterized by FT-IR spectroscopy, scanning electron microscopy, energy dispersive X-ray
spectroscopy and contact angle analysis. We have confirmed the thromboresistance of albumin film
by in vitro measurement of adsorption of human fibrinogen and platelets. We found that albumin
film controlled the adsorption of fibrinogen evidenced by measurement of fluorescently labeled
protein and adhesion force measurement. Human platelet adhesion was significantly lower on
albumin coated compared to uncoated substrates. Smooth muscle cells play a key role in progression
of intimal hyperplasia and hence we assessed the proliferation, hypertrophy and contractile state of
cells in static and flow conditions. A vascular simulator was employed to provide forces of cyclic
strain and flow shear to smooth muscle cells on albumin coated and uncoated ePTFE grafts. It was
found that albumin film controlled proliferation and maintained the contractile state of smooth
muscle cells on nitinol and ePTFE substrates. We developed a flow circulation loop model to assess
the response of fibrinogen and platelets on albumin coated and uncoated e PTFE grafts. A
significantly lower adsorption of fibrinogen and platelet adhesion was measured on albumin coated
e PTFE grafts compared to uncoated grafts.
Exhibiting strong adhesion strength to polymeric and metallic substrates, human albumin film
fabricated using PGMA as an anchoring layer has been shown to shield the surface from adhesive
protein fibrinogen and prevents adhesion of platelets thereby providing an anti-thrombogenic layer.
ii

Human albumin has been shown to maintain a controlled proliferation profile and spindle shaped
morphology of vascular smooth muscle cells with increased expression of contractile protein smooth
muscle alpha actin mitigating the complication of intimal hyperplasia post a percutaneous
interventional procedure and bypass surgery.
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CHAPTER 1
INTRODUCTION

Vascular implants and devices employing metals and synthetic polymers have frequently been
associated with adverse clinical outcomes including, thrombosis, cell hyperproliferation and
inflammation. The primary causes of the short-term and long-term failure of endovascular stents and
small-diameter vascular grafts are thrombosis and intimal hyperplasia. Synthetic polymers such as
ePTFE and Dacron have shown long term stability and inertness, however, their hydrophobic nature
and low hemo-compatibility limit their success in low-diameter vessels [1-6]. A primary reason
behind failure of synthetic polymers used for small diameter grafts has been low flow environments
which has limited their application in large diameter vessels [7,8]. Low flow shear stress promotes
strong and irreversible binding of adhesive protein fibrinogen with platelets resulting in platelet
activation and aggregation, release of PDGF and thrombosis [9-13]. Myointimal hyperplasia has also
been observed in those cases. Different surface modification techniques, bioactive coatings and
approaches to facilitate endothelialization of surfaces have been proposed as means to prevent
thrombosis and mitigate hyperplasia [72-76], however, there is still a need for an ideal vascular graft
material alternative to autologous vessels with excellent clinical outcomes and long term patency
rates.
We propose that fibrinogen adsorption, platelet adhesion and smooth muscle hyperplasia &
hypertrophy will be prevented with the use of human serum albumin coating.
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Research Significance
Small diameter grafts fail as a result of intimal hyperplasia and luminal surface thrombosis leading
to vessel occlusion [5-8]. Normal blood vessels lined by inactivated endothelial layer maintain the
anti-thrombotic, anti-inflammatory and fibrinolytic properties [29]. Autologous blood vessels such
as saphenous vein and internal mammary artery lined by endothelial cell layer function well as
compared to synthetic conduits [30,31]. However, due to poor vein harvest or poor vein quality in
patients undergoing peripheral arterial reconstructive procedures, there is an unavailability of
adequate autologous grafts [32]. Vessel injury due to surgerical procedure causes platelets and
leukocytes to bind to the surface and anastomosis site. Adherent platelets and leukocytes release
growth factors and molecules such as platelet derived growth factor, thrombospondin, bthromboglobulin and reactive oxygen species [33,34]. These molecules can trigger a thrombotic
response as well as promote proliferation and migration of smooth muscle cells leading to intimal
hyperplasia at the anastomosis [35-37]. Early failure of the graft results from thrombosis and late
failure results from intimal hyperplasia [38]. Intimal hyperplasia results in abnormal thickening of
the vessel with lumen narrowing. Owing to the high propensity for intimal hyperplasia and
thrombosis in low flow environments, application of synthetic grafts is limited to large diameter
vessels with high flow rates [39-41]. Blood-biomaterial interactions play a major role in facilitating
a thrombotic response. Upon implantation, the biomaterial surface is encapsulated by an adsorbed
protein layer that triggers the activation, adhesion and aggregation of platelets and activates the
coagulation cascade resulting in the formation of a thrombus on the surface [42-44]. The biomaterial
can activate the complement system resulting in an inflammatory response [45]. Thus, the
biomaterial surface, and the adsorbed protein layer, becomes an important determinant of its
biocompatibility and long-term success. Adhesive proteins such as fibrinogen and von-Willebrand
factor have been shown to facilitate activation, adhesion and aggregation of platelets [46-48].
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Lacking amino acid sequences that can bind to platelet receptors, serum albumin has been shown to
passivate the surface of a biomaterial against adhesion of platelets [49-52]. However, rapid
degradation of the protein from the surface [53-55] and change in secondary structure conformation
of albumin has been shown to be critical in facilitating the adhesion of platelets [56].
Research Innovation
Synthetic polymers employed in vascular grafts delay endothelialization and facilitate adhesion of
platelets [57-59]. In the present study, we have employed a technique to design human serum albumin
(HSA) films on substrates using poly(glycidyl methacrylate) (PGMA) as an anchoring layer (Fig.1).
HSA is the most abundant protein present in human blood. It has been shown to passivate material
surfaces thus blocking sites for adsorption of other proteins and adhesion of platelets and cells [6067]. PGMA has been known for its high surface density and affinity for reacting with amines [68].
PGMA binds HSA through an easy nucleophilic addition reaction that results in the formation of
strong covalent bond with the surface. Epoxy groups of PGMA act as spacer molecules and bind to
albumin, keeping them close to their native secondary structure conformation [69-71].

Aim 1: Fabrication, characterization and assessment of human serum albumin film on
poly(glycidyl methacrylate) (PGMA) anchoring layer for enhanced hemocompatibility and
mitigation of neointimal smooth muscle cell hyperplasia.
Hypothesis: Human Serum Albumin film will reduce the incidence of thrombosis and restenosis by
preventing theadhesion of platelets and mitigating the proliferation and growth of smooth muscle
cells on a metallic surface.
Rationale: Human Serum Albumin is the most abundant protein present in human blood. It has been
shown to passivate material surfaces thus blocking sites for adsorption of other proteins and adhesion
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of platelets and cells [14,15-21]. In this study, PGMA, a polymer with epoxy functionality, is used
to form a reactive anchoring polymer layer since the reactions of epoxy groups are quite universal
and can covalently anchor PGMA to the substrate surface [22]. The glycidyl methacrylate units
located in the “loops” and “tails” sections of the attached PGMA chain could serve as reactive sites
for the subsequent attachment of (macro) molecules with complementary functional groups. PGMA
is also known for its high surface density and affinity for reacting with amines [23].

Aim 2: Fabrication and characterization of human serum albumin films on ePTFE graft
surfaces for enhanced hemocompatibility and adhesion strength under physiologically relevant
flow shear stress conditions.
Hypothesis: Human albumin with high adhesion on ePTFE surface will reduce the incidence of
thrombus formation.
Rationale: Exposure of ePTFE to blood results in rapid irreversible protein adsorption by
hydrophobic interaction [24]. Proteins adsorbed on the surface activate extrinsic pathway of blood
coagulation resulting in the formation of fibrin and platelet deposition. It is imperative to develop
functional groups on ePTFE surface to enhance surface wettability and reduce rapid substantial
protein and platelet adhesion. Strong adhesion strength of a vascular coating is essential for long
term beneficial effects in regulating cellular and platelet growth to maintain vascular integrity and
clinical patency.

14

Aim 3: Assessment of potential of albumin film to mitigate intimal hyperplasia in a smooth
muscle cell-platelet co-culture model under physiologically relevant forces of flow shear.
Hypothesis: Human serum albumin film on ePTFE surface will reduce hyper-proliferation and
hypertrophy of vascular smooth muscle cells under clinically relevant mechanical flow shear forces
observed in small diameter blood vessels.
Rationale: Adherent platelets on the hydrophobic ePTFE surface release growth factors such as
platelet derived growth factor (PDGF) and basic fibroblast growth factor (bFGF) to stimulate
migration and proliferation of vascular smooth muscle cells. Synthetic grafts perform well in largediameter, high-flow, low resistance locations such as the aorta and the iliac and proximal femoral
arteries. ePTFE has not been successful as small-diameter (2-5mm) vascular grafts replacement for
the below knee popliteal artery or the tibial vessels [25,26]. Low blood velocity allowing more
interaction between blood and biomaterial has been found to a major reason behind low performance
of synthetic grafts in small diameter vessels [27,28]. Anastomotic intimal thickening in low shear
stress conditions can cause substantial decrease in the luminal diameter of the vessel. This is one of
the major obstacles in the development and application of small diameter vascular graft.
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CHAPTER 2
ANTI-THROMBOGENIC COATINGS FOR VASCULAR DEVICES

Abstract
Thrombosis and restenosis remain major complications after bypass graft surgery. Autologous
vessels are the gold standard for bypass graft surgeries. However, due to unavailability of healthy
autologous arteries, synthetic polymers have been widely employed for the fabrication of vascular
grafts. Even though commonly employed synthetic polymers such as Teflon, Dacron and
polyurethanes offer the advantages of being stable in biological environments and non-toxic, they
have shown poor clinical outcomes as small-diameter vessel replacements because of high rates of
thrombosis in low flow environments. Currently, no material has been developed that has the same
patency rates as autologous vessels. Many attempts have been made to design coatings that reduce
the incidence of thrombosis in vascular graft conduits. This review attempts to provide a summary
of the coatings employed to prevent the incidence of thrombosis and improve hemocompatibility of
vascular grafts.
Keywords: Vascular grafts, thrombosis, synthetic polymer conduits, anastomotic hyperplasia
Introduction
Atherosclerosis is the major cause of mortality and morbidity in the developed world, causing nearly
$300 billion USD annually in revascularization treatments [1]. Atherosclerosis is a chronic,
progressive disease of the vessel wall intima. Atheromatous plaque is the characteristic lesion, with
a central core of lipid and cholesterol crystals and cells such as macrophages, smooth muscle cells
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and foam cells with necrotic debris, proteins and degenerating blood fragments [2,3]. The major
complications of atherosclerosis result from progressive obstruction of a vessel lumen or disruption
of a plaque followed by thrombus formation.
Percutaneous interventions have increased the longevity of patients suffering from atherosclerosisaffected vessels [4]. Balloon angioplasty involving insertion and inflation of a balloon into a stenosed
artery is used to break the plaque and dilate the artery to restore blood flow. A metallic stent
implantation is often accompanied by balloon angioplasty to prevent the incidence of elastic recoil
and restenosis by the release of an antiproliferative agent. In the case of elderly and diseased patients,
bypass or replacement of the stenosed artery is employed to restore blood flow. The patient’s own
blood vessel such as the saphenous vein or internal mammary artery is the preferred choice for bypass
[99,100]. However, due to unavailability of an autologous healthy vessel and/or need for multiple
surgeries, synthetic vascular conduits have been employed to bypass stenosed arteries. [5,6,7,8].
Vascular grafts made of Teflon were introduced in 1957 and have proven superior to all other
synthetic prostheses due to rapid healing, minimal tissue reaction and gain of strength after
implantation. Edwards and collaborators showed that tubular knitted Teflon was easy to suture, inert
and biocompatible [9,10]. In late 1960s, a paste extrusion protocol was developed to create a
fluorocarbon polymer ePTFE by heating, stretching and expanding Teflon to create a microporous
graft with inertness and improved tissue adhesion [11]. ePTFE formed into sheets has solid nodes
interconnected by fine fibrils, and the intermodal distance can be changed to alter the graft porosity
[10].
In 1958, DeBakey et al, introduced the Dacron (polyethylene terephthalate) (PET) graft, which has
demonstrated high strength and stability for over 10 years without deterioration, with 5-year patency
rates of 93% for aortic replacements [12] and 43% for small-diameter vessels (below the knee) [98].

25

Polyurethane (PU) has been used as a vascular conduit owing to its good elasticity and superior
compliance [13] However, PU-based vascular grafts have been susceptible to degradation in vivo
[14]. Biodegradable polymers polylactic acid (PLA) and poly-glycolic acid (PGA) have been
explored as vascular graft conduits because they can biodegrade without leaving toxic residues.
However, they have been prone to undergo aneurysmal dilation and rupture prior to healing. PGA
has been shown to rapidly degrade due to a hydrolysis reaction [15].
ePTFE and Dacron have been shown to have good mechanical stability to be promising candidates
as vascular graft replacements. Dacron has shown to have better compliance than e PTFE which is
measured as the ratio of incremental volume change to incremental transmural pressure change (%
diameter change/mm mercury). Both PET and ePTFE have been shown to have the similar patency
rates for 3 (61%) and 5 years (45%) [16,17] compared to 5 (77%) [105] and 10 year (50%)[106]
patency rates of autogenous vein grafts as femoropopliteal vessel replacements.
Synthetic grafts perform well in large-diameter, high-flow, low resistance locations such as the aorta
and the iliac and proximal femoral arteries. In contrast, Dacron and Teflon have not been successful
as small-diameter (2-5mm) vascular grafts replacements for below the knee popliteal artery or the
tibial vessels [18,19,20,21,22]. Low blood velocity allowing more interaction between blood and
biomaterial has been found to a major reason behind low performance of synthetic grafts in small
diameter vessels [23, 24]. ePTFE has been shown to provide satisfactory performance as a conduit
for femoropopliteal reconstruction (in the case of nonavailability of saphenous vein) due to its
smoothness, easy care and no required pre-clotting. [25, 26]. However, despite recent advances in
developing biocompatible graft materials, the need for a nonthrombogenic, compliant and
endothelial-cell-growth-promoting material remains a challenge in tissue engineering and
biomaterials research.
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Vascular graft pathology
Artery-graft anastomotic sites are the primary areas where neo-intimal hyperplasia is observed.
Factors that contribute to loss of patency are vessel injury, adsorption of plasma proteins, neo-intimal
hyperplasia, thrombosis and hemodynamic factors.
1. Vessel injury
Graft surgery causes damage to the intima, media and adventitia of the vessel. Injury to the vessel
wall and denudation of the endothelial layer triggers the contact of platelets with adhesive proteins
such as collagen, von Willebrand factor, fibronectin and laminin resulting in platelet activation and
aggregation [27] and contact of smooth muscle cells with the inflammatory and procoagulant blood
constituents. Activated platelets release cytokines such as platelet-derived growth factor (PDGF) and
fibroblast growth factor (FGF), which facilitate migration and proliferation of smooth muscle cells
from the media to the intima. Proliferating smooth muscle cells release cytokines in an autocrine and
paracrine fashion and synthesize extracellular matrix, causing formation of neointima.
2. Attachment of plasma proteins
When a synthetic graft is implanted, the luminal surface of the graft becomes coated with a layer of
plasma proteins. The most abundantly present albumin is replaced by the heavier adhesive proteins,
predominantly fibrinogen, which forms a pseudo-intima [28]. Endothelial cells serve as a
nonthrombogenic surface covering the inner layer of a blood vessel called neo-intima. After a graft
implantation, only the anastomosis site becomes covered by endothelium, and thus the inner lining
of the synthetic grafts remain covered by the pseudo-intima platelet-protein layer even weeks after
implantation. Dislodgement of the pseudo-intima layer can cause distal embolization or a flap-valve
formation, both causing acute obstruction.
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3. Anastomotic hyperplasia
Intimal hyperplasia is a healing response to injury in the vascular wall that promotes abnormal
thickening of the vessel with lumenal narrowing. Intimal hyperplasia involves migration and
proliferation of vascular smooth muscle cells from the media to the intima with subsequent release
of extracellular matrix proteins, which cause narrowing of the lumen. Patency of synthetic grafts
becomes impaired due to intimal hyperplasia at the anastomotic regions. While medial cell
proliferation begins immediately after injury, peaks in 2 days and declines by 7 days, intimal cell
proliferation peaks at 1 week and declines by 2 weeks [29]. The number of smooth muscle cells
remains fairly constant after 2 weeks; however, the cells increase in size up to 8 weeks due to
accumulation of extracellular matrix [30]. Mismatch in the mechanical properties of the native vessel
and synthetic graft alsocause1 hyperplasia of smooth muscle cells [31].

4. Thrombosis
Thrombosis involves activation of the coagulation cascade and complement system and activation
of cellular components of blood such as leukocytes and platelets. Together these cause the formation
of a blood clot that obstructs blood flow [33].
In the blood coagulation cascade (Figure 2.1), inactive enzymes (zymogens) are enzymatically
serially activated due to surface contact or proteolytic cleavage. The cascade is initiated either by
intrinsic or extrinsic pathway from the site of endothelial injury. The pathways converge to cause the
activation of thrombin from prothrombin, which catalyzes the conversion of fibrinogen to a fibrin
clot, which is stabilized to an insoluble fibrin gel upon activation by factor XIII [32].
The complement system is involved in regarding biomaterials as non-self and facilitating an
inflammatory response. It comprises of more than 20 plasma proteins and two pathways, classical
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and alternate which form C3 convertases and C5 convertases catalyzing formation of C3a (an
anaphylatoxins) and C3b and C5a (an anaphylatoxin) and C5b respectively resulting in the formation
of membrane attack complex causing cell lysis[33]. Biomaterials activating complement system
facilitate the interaction of factor B with surface-bound C3b as opposed to nonactivating surfaces
that favor binding of factor H with C3b[34].
Injury to the vessel wall activates endothelium, which causes enhanced secretion of prostacyclin
(PGI2), von-Willebrand factor (vWF) and increased expression of cell surface adhesion molecules
[32,36] such as PECAM, ICAM-1, P-selectin, V-selectin and VCAM-1, which bind to leukocytes
and platelet receptors, causing platelet aggregation.
Leukocytes facilitate platelet recruitment and activation, promoting further leukocyte adhesion,
fibrinolysis and thrombin formation [35]. Sticky activated leukocytes bound to the damaged
endothelial layer and biomaterial surfaces express high levels of membrane receptors CD11b and
PSGL-1, which bind with GP-IIB/IIIA and P-selectin, respectively [33] expressed on activated
platelets facilitating the incidence of thrombosis.
The platelet-mediated response resulting in thrombosis on biomaterials comprises plasma protein
adsorption, leukocyte adhesion, platelet aggregation and blood coagulation. Thus, minimizing
surface-induced platelet adhesion is a central goal in designing hemocompatible biomaterials.
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Figure 2.1 Blood Coagulation Cascade

Hemodynamic factors
It has been shown that reduction in shear stress causes neo-intimal hyperplasia [37,133,134].
Reduction in shear stress also causes release of vasoactive substances such as nitric oxide,
prostacyclin, mitogens such as platelet derived growth factor (PDGF) and basic fibroblast growth
factor (bFGF), activation of vascular cell transcription factors, protein synthesis and rearrangement
of cytoskeleton causing vessel thickness [38,135].
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Shear stress has been proven to vary with arterial diameter. To maintain a constant shear force,
arterial diameter increases or decreases in response to changes in blood flow[139]. Wall shear stress
affects aggregation of platelets [39]. Low shear rates promote platelet aggregation. High shear rates
cause reduced size of platelet aggregates, however, shear stress values greater than 70 dynes/cm2
cause an exponential increase in platelet aggregation [40,41].
Cells in the vessel wall are exposed to three types of mechanical forces, 1) stress caused by pressure
of the blood perpendicular to the vessel wall, 2) circumferential wall stress or hoop stress exerted as
a result of the stretching of the vessel wall by the transmural pressure gradient, 3) fluid shear stress,
the friction at the interface between flowing blood and the apical surface of endothelial cells [140].
In the case of denudation of endothelial cells after the trauma of a bypass surgery, smooth muscle
cells and fibroblasts are exposed to blood flow. These stresses regulate the function and dynamic
remodeling of the vessel wall and also contribute to development of the pathological conditions. A
string correlation between low shear stress and atheroma formation was first postulated in 1969.
Numerous preclinical and clinical studies have proved that physiological high shear stress inhibits
smooth muscle cell proliferation while low shear stress causes disturbed and turbulent flow, low flow
velocity and recirculation flow significantly contributing towards progression of neo-intimal
hyperplasia in those areas and also by upregulating PDGF [42,43, 101,102,103].

Effect of shear stress on plasma proteins:
High shear stress conditions facilitate the weak and reversible adsorption of von Willebrand factor
and GP-IB/IX/V receptors of platelet, a process known as platelet tethering to slow down platelets
under blood flow [44,45]. At low shear stress conditions (<12 dynes/cm2), surface adsorbed
fibrinogen forms a strong complex with GP IIB/IIIA receptors on the platelet membrane [130]. The
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adsorption-induced secondary structure conformation change of fibrinogen has been shown to be a
critical determinant correlated with the adhesion of platelets [131]. Both fibrinogen and von
Willebrand factor work synergistically to promote platelet adhesion after vessel injury and on a
biomaterial [125, 126]. Other integrins expressed on the platelet membranes GP-IIA/IB, GP-VA/BI
and GP-VIA/BI promote adhesive interactions with ECM proteins such as collagen, fibronectin and
laminin, respectively [127, 128, 129].

Methods employed to reduce thrombogenicity
Poor patency rates and clinical outcomes of synthetic conduits in small-diameter vessels have led to
intensive research interest in surface modification of biomaterials. These include surface coatings to
reduce the incidence of thrombogenicity and neointimal hyperplasia and to improve tissue adhesion
and healing. Also, because the required mechanical properties such as suture strength and vesselwall thickness are provided by existing synthetic conduits, surface modification strategies have been
employed to achieve the ideal healing response. Three approaches have been widely employed to
reduce the incidence of thrombogenicity — surface modification, endothelialization and bioactive
coatings. These coatings include: carbon, poly-ethylene glycol, heparin, nitric oxide,
thrombomodulin, hirudin, salicyclic acid, albumin among others.
Carbon
Carbon coating enhances electronegativity of a surface, thus reducing the propensity toward platelet
binding. A homogeneous and stable coating of graphite on polyester grafts has shown reduced
incidence of platelet activation, adherence and spreading in comparison to noncoated and control
grafts [46]. However, graphite-coated polyester grafts were found to be difficult to suture. High
density carbon-coated Dacron grafts have shown less thrombosis and thinner fibrin capsule than
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noncoated control grafts [47]. However, surface irregularities have caused poor performance in other
studies [48]. Carbon-coated grafts have shown short-term mitigation of platelet adhesion; however,
overall patency rates were not higher when compared to uncoated controls [49]. Robertson and
collaborators demonstrated the efficacy of diamond like carbon coatings for anti-microbial and antithrombogenic properties [145]. In clinical trials for below knee popliteal and distal bypass grafting
did not show significant improvement in patency rates 2 years after implantation [138].

Hydrophilic coatings
Polyethylene glycol (PEG), polyethylene oxides and polyurethanes are the most frequently employed
hydrophilic polymers as coatings as they prevent protein adsorption. PEG can be readily immobilized
on surfaces using silane conjugation techniques [141]. The length and degree of branching of these
materials affect the degree of platelet repulsion. PEG has been widely used to immobilize protein
and other biomolecules such as heparin to render a thromboresistant surface: PEG chains allow
conservation of 3D structure and mobility of biomolecules. Long chains of ethylene oxide create a
high dipole moment, which causes high degrees of hydration to repel surface proteins. Surface
modification with PEO has been researched by investigators by covalent grafting and physical
adsorption. PEO- and PEG-coatings on ePTFE grafts have provided short term protection to platelet
adhesion and intimal hyperplasia [52, 107, 108]. However, in vivo results have been inconsistent
with in vitro results, and no clinical studies have yet been performed to test the efficacy of these
coatings in reducing thrombosis incidence [142]. Further, it has been speculated that creating a
hydrophilic surface is not sufficient to reduce thrombosis incidence [143]. Thus, the need for
bioactive coatings to prevent adhesion of platelets is essential to create a thromboresistant surface.
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Heparin
Heparin is a sulfated glycosaminoglycan that has been shown to inhibit blood coagulation by binding
to antithrombin III, a serine protease inhibitor that inactivates pro-coagulant thrombin (activated
factor IIa) and other proteases involved in the blood clotting process [53, 110]. Lev and collaborators
compared rates of thrombosis in heparin-coated (0.8%) and noncoated stents (6.1%) in patients
undergoing percutaneous intervention procedures [54]. In this study, Heparin-coated stents showed
improved 30-day outcomes as compared to noncoated stents [54]. Lin and collaborators found that
heparin-coated small caliber vascular grafts caused mitigation of neointimal hyperplasia and platelet
deposition in aortoiliac reconstruction in a baboon model [113]. Nie and collaborators demonstrated
heparin as an effective coating for promoting endothelialization and anti-thrombogenic potential
[144]. Preclinical and clinical studies on covalently bound heparin have been shown to render
surfaces thromboresistant. However, covalently bound heparin has been shown to have limited use
due to loss of functional activity as a result of improper immobilization and rapid degradation [55,
112]. Heparinized surfaces have also been shown to be centers for affinity of adhesive proteins such
as collagen, fibrinogen and von Willebrand factor [56]. Heparin-bonded Propaten® vascular grafts
(W.L. Gore and Associates) are manufactured using Carmeda® Bioactive Surface modification [58,
109]. The graft has shown promising results for lower extremity bypass with lesser rates of
thrombosis [59, 111]; however, the clinical trials were non-randomized and retrospective which
brings into question the significance of the results.

Nitric oxide-releasing biomaterials
Nitric oxide (NO) has been shown to inhibit smooth muscle cell proliferation and to inhibit platelet
aggregation and activation [57, 60]. Materials facilitating the release of NO at the graft site have been
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widely employed to reduce the incidence of thrombosis. Hydrophobic polymer films releasing
diazeniumdiolate, an NO-donating compound, was shown to facilitate the release of NO for 72 hours,
partially inhibiting platelet adhesion [61]. Polyurethane-releasing nitric oxide by a diazeniumdiolatemodified nitric oxide-producing peptide was also shown to reduce platelet adhesion and smooth
muscle cell proliferation and promote endothelial cell growth. [62]. NO-releasing polyurethane
inhibited thrombus formation in a sheep arteriovenous bridge graft model for up to 21 days [63].
However, none of the studies have been capable of facilitating the release of NO for a sufficiently
long time period to prevent incidence of thrombosis.
The effect of nitric oxide is mediated by cyclic 3’5’- guanosine monophosphate (c GMP) secondary
messenger pathway. Sildenafil, a phosphodiesterase inhibitor, facilitates accumulation of c GMP,
enhancing NO function offering an alternative as anti-platelet adhesive grafts [64]. However, the
effect of NO as a platelet inhibitor been shown to be less relevant in mouse models [65].

Thrombomodulin
Thrombomodulin (TM) expressed by endothelial cells forms a complex with thrombin causing the
release of protein C (aPC), a potent inhibitor of Factor V and Factor VIII of the blood coagulation
cascade [66]. TM has also been shown to inhibit leukocyte adhesion and endothelial cell apoptosis.
TM ligated using C-terminal azide moiety on PU-coated PTFE grafts maintained activity for up to 2
weeks [67]. However, the modified surface was not able to inhibit in vivo platelet adhesion using a
baboon arteriovenous shunt model [68].
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Hirudin
Hirudin, produced by medicinal leeches (Hirudo medicinalis), is a potent inhibitor of thrombin.
Hirudin has been an effective therapy for patients with unstable angina. Polyester grafts with
covalently bound hirudin via an albumin coating was shown to be capable of inhibiting thrombin
activity under dynamic flow conditions [69]. However, the hirudin coating degraded in 7 days. PLLA
vascular grafts with immobilized hirudin using a PEG spacer via EDC/NHS chemistry in a rat carotid
artery interposition model was shown to maintain better patency at one month (83%) as compared to
control grafts (50%) promoting endothelial cell growth and less infiltration of macrophages and
monocytes [70].

Salicylic Acid
Salicylic acid and its derivatives have been used as therapeutic agents. Aspirin®, a form of salicylate,
inhibits prostaglandin biosynthesis blocking thromboxane formation in blood platelets [50].
Hydrophilic acrylic polymer coatings bearing salicylic acid residues on Dacron grafts showed
improved thrombogenicity as compared to uncoated controls [104]. Rodriguez and collaborators
created coatings of a polyacrylic derivative of triflusal (2-aqcetyloxy-4trifluromethyl) benzoic acid
(a derivative of salicylic acid) that allowed slow release of triflusan, improving platelet antiaggregation without an anti-thrombotic drug [51].

Endothelial cell-seeding of vascular grafts
Early failure due to thrombosis is more frequent in synthetic grafts compared to vein grafts because
of the presence of an endothelial cell lining in vein grafts, which prevents thrombosis and intimal
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hyperplasia, thereby improving patency rates. Further, complete regeneration of the endothelial layer
does not occur in humans as compared to animals.
Herring, Mansfield and collaborators introduced the idea of extraction and implantation of
autogenous endothelial cells (endothelial cell seeding) to decrease the incidence of thrombosis and
improve patency of synthetic grafts [71]. The endothelial cell layer regulates vascular tone and
permeability, thrombosis, inflammation and fibrinolysis by expression and secretion of antiinflammatory molecules.
Intact endothelium releases potent vasodilators such as nitric oxide (NO) and prostacyclin (PGI2),
which prevent platelet activation, aggregation and adhesion to the endothelium. Therefore,
endothelium has been shown to prevent thrombosis formation [71].
A number of investigators have attempted to coat an EC layer on biomaterials. However, the attempts
have not been successful due to difficulties in isolation and seeding of endothelial cells in large
numbers in a short time frame and under sterile conditions. It has been proven that a confluent layer
of ECs displays a nonthrombogenic profile. However, endothelial cells appear to be more
thrombogenic at subconfluent densities [72]. The healing process of synthetic prostheses remains
incomplete in humans, with formation of a fibrous capsule, minimal capillary ingrowth and sparse
lining of endothelial cells in the lumen [73]. Uncoated e PTFE and Dacron have been shown to
promote poor endothelial cell attachment and endothelial cell retention [74,114]. This has
necessitated the importance of a coating to improve the adherence, growth and morphology of EC
culture. Basement membrane proteins such as fibronectin [75], arginine-glycine-aspartate (RGD)containing peptide (active component of fibronectin) [76], collagen [95], laminin [96] have shown
improvement in endothelial cell layer adhesion on untreated graft materials. In a porcine interposition
graft model, coating ePTFE with fibronectin improved cell growth and endothelialization [77].
However, coating such basement membranes on the biomaterial increases the incidence of
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thrombosis as a result of exposure to blood and/or loss of endothelial layer due to shear [78]. A twostage seeding process involving extraction of endothelial cells followed by prolonged culture to
increase cell number and then seeding onto the graft material (a process called sodding) has been
proposed to be better than a single seeding process, which has shown no significant response in
clinical trials. A reason behind inefficiency of the single-seeding process is cell loss due to exposure
to blood flow. After exposure to blood flow shear, 70% of cell loss occurs within 45 minutes [79]. e
PTFE grafts have been shown to have 10+7% endothelial cell attachment and 4+3% endothelial cell
retention [80]. Preconditioning of endothelial cells with long-term flow shear has improved retention
in in vitro studies [81].

Preclotting of grafts
Porosity (for transfer of nutrients, fluid, ions and ingrowth of tissue) of a graft is an important
parameter for healing and long term patency. However, porous grafts are permeable to blood during
implantation. Impregnation of graft pores with the patient’s blood is employed to prevent initial leak.
Investigators have studied biodegradable coatings that will degrade over time to support healing.
Albumin is shown to be advantageous in passivating surfaces. Albumin-coated prostheses are now
commercially available in Europe and Canada and are under trials in the US [82].
Gelatin with poor antigenicity has been used under the trade name Gelseal Triaxial graft. It has been
shown to promote cellular growth and tissue integration [83]. Collagen has been proven
advantageous in promoting faster healing and in endothelial layer formation; however, collagen has
been associated with immunogenicity and thrombogenicity issues [97].
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Albumin
Albumin is the most abundant protein present in the blood [28]. Because of its abundance, it has been
shown to passivate surfaces and is considered a thromboresistant protein. Adsorption of albumin to
medical device surfaces has been shown to minimize platelet activation and adhesion and activation
of complement [84,85,86].An albumination has been shown to render surfaces nonthrombogenic and
noninflammatory by minimizing adsorption of adhesive proteins on the surface and adhesion of
platelets and leukocytes [115, 116, 117].
Albumin adsorbs rapidly. However, it is replaced by other adhesive proteins such as fibrinogen, von
Willebrand factor and factor XII [87]. Albuminated surfaces have also been shown to go undetected
by microorganisms [88, 89], and thus can minimize the incidence of infection.
Attempts to create surfaces coated with albumin by physical adsorption become displaced by other
proteins. Investigators have employed methods to either promote albumin adsorption on a surface or
coat surfaces with albumin [121,122,123]. However, physical adsorption of albumin on a surface
causes rapid degradation and reduced passivation effect. Covalent binding methods have been
employed to enhance the longevity of albumin coating on a surface [118, 119, 120]. Immobilization
of straight chain 16 or 18- carbon alkyl groups on surfaces was achieved to selectively adsorb
albumin for similarity to high-albumin fatty acid binding sites of albumin [90]. This method caused
increased affinity of the surface towards albumin; however, it also enhanced adsorption of other
proteins such as fibrinogen and subsequently encouraged denaturation of adsorbed proteins and
platelet activation.
Grafting cibacron dye on a surface was attempted to selectively adsorb albumin on the surface [91].
CB has structural similarity to bilirubin, which is an endogenous ligand associated with albumin in
vivo. This process increased adsorption of albumin on the surface. However, improper presentation
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of CB affinity ligand on the surface and inaccessibility of ligand to plasma protein were the major
limitations of this process.
Immobilization of a monoclonal antibody (Mab) against albumin on a surface showed increased
adsorption of albumin [92]. However, nonuniform immobilization of the ligand caused irregular
adsorption of albumin on the surface and reduced functional activity.
Glutaraldehyde cross-linked human albumin-coated polyester knitted grafts have been shown to
provide short-term prevention of thrombus formation by reduced platelet and leukocyte adhesion and
aggregation.[93,94].Albumin-coated knitted Dacron grafts have been shown to reduce postoperative
inflammation[132l However, significant difference from the controls long term was not observed.
This might have been because of rapid degradation of albumin from the surface or because of surface
adsorption-induced denaturation.
Structural stability of albumin on a surface has been considered an important factor in reducing
activation and adhesion of platelets. Beyond a critical degree of unfolding, albumin has been shown
to allow platelet adhesion and aggregation [124]. Hence, there is still need of immobilization
techniques to coat albumin on a surface in such a way that its structural stability is maintained, which
would allow it to retain its native conformation to prevent fibrinogen adsorption and platelet
adhesion.
Human serum albumin immobilized on a poly(glycidyl methacrylate) PGMA anchoring layer [136]
has been shown to prevent hyperplastic response of rat aortic smooth muscle cells up to 30 days and
vascular platelet adhesion under flow shear conditions [137]. PGMA covalently bonded to albumin
allowed its secondary structure conformation to remain intact, thereby preserving albumin’s
functional property of preventing adhesion of platelets and preserving long term stability on the
surface.
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Conclusions
Developing antithrombogenic coatings for vascular devices is an area of wide interest. Despite
extensive research on designing surfaces that reduce the incidence of thrombosis, no one has been
able to develop a biomaterial alternative to autologous vein grafts, which have excellent clinical
outcome in terms of reducing platelet adhesion and promoting endothelial healing. Integrating our
knowledge of blood-biomaterial interactions, tissue engineering and biomaterials, there is a need to
develop a new generation of vessel constructs the would be nonthrombogenic and selfendothelializing and mitigate inflammatory and hyperplastic responses of vascular smooth muscle
cells for superior biocompatibility and long-term clinical patency rates.
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CHAPTER 3
HUMAN SERUM ALBUMIN FILM FOR ENHANCED HEMOCOMPATIBILITY AND
PREVENTION OF INTIMAL HYPERPLASIA

Abstract:
Introduction: Restenosis and thrombosis are two major clinical complications of endovascular
stents. In this study, a novel biopolymeric coating made of human serum albumin (HSA) grafted on
poly (glycidyl methacrylate) (PGMA) is proposed to reduce neointimal hyperplasia by inhibiting
smooth muscle cell (SMC) proliferation and shielding fibrinogen (Fg) adsorption and platelet
adhesion, thereby reducing thrombosis incidence.
Materials and Methods: Plasma treated Nitinol (NiTi) discs were surface modified with 0.5%
wt/vol PGMA (Mn=176000g/mol) in chloroform to produce an epoxy rich anchoring layer followed
by dip-coating of 5% wt/vol HSA. Samples were then annealed at 150 ̊C vacuum oven for 1 hour.
HSA grafted samples were incubated in NHS-Rhodamine- labeled human plasma fibrinogen solution
in phosphate buffer for 1 hour at 37 ̊C. Fluorescence was measured at 525nm and 575nm. Change in
secondary structure conformation of annealed albumin was assessed by CD spectroscopy. Plateletrich plasma isolated from fresh human blood was incubated on HSA nanofilms for 1 hour at 37 ̊C.
Platelet adhesion was measured by lactate dehydrogenase (LDH) assay. Sprague Dawley rat aortic
SMCs were cultured on HSA nanofilms for 5, 15 and 30 days in DMEM with 10% FBS. Cell
proliferation was assessed by MTT assay. Expression of contractile marker smooth muscle alphaactin was assessed by a cell based ELISA assay.
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Results: The thickness of the PGMA (18±0.4nm) and HSA coatings (102±4.5 nm) was determined
using ellipsometry. There was significantly less human plasma fibrinogen adsorption on HSA
nanofilms (90±9.8ng/mm2; p = 0.023) as compared to bare NiTi. LDH assay showed significantly
less platelet adhesion on HSA films compared to NiTi under static (p = 0.014) and shear conditions
(p = 0.021). HSA films allowed significantly less rat aortic VSMC proliferation over a period of 5,
15 and 30 days as compared to bare NiTi (p =0.027, p =0.031 and p =0.032 respectively). The
difference in the smooth muscle alpha actin expression on HSA for 5 and 15 days (p = 0.063) was
insignificant as compared to bare NiTi. VSMCs cultured on HSA at Day 30 expressed significantly
higher smooth muscle alpha actin content as compared to bare NiTi (p = 0.038).
Keywords: Human serum albumin; thrombosis; restenosis; synthetic bypass grafts

3.1 Introduction
Endovascular stent deployment and bypass graft surgery are the most commonly employed
revascularization procedures to treat blood vessels stenosed by atherosclerosis. However, stent and
graft implantation are often associated with two major complications, restenosis and thrombosis.
Restenosis is the re-narrowing of a revascularized blood vessel due to hyperplastic response of
smooth muscle cells (neointimal hyperplasia). Thrombosis causes occlusion of the blood vessel due
to platelet adhesion and aggregation at the site of endothelial denudation and on the thrombogenic
surfaces of stent struts and grafts. The occlusion is a result of activation of the coagulation cascade,
which impedes blood flow [1,2,3]. Anti-platelet treatment has been shown to increase the risk of
hemorrhagic complications [4] and ischemic complications [5]. Although rates of restenosis and
target vessel revascularization are reduced after deployment of drug-eluting stents releases
pharmacological agents [6,7], the incidence of in-stent thrombosis is not decreased when drug-
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eluting stents are compared to bare-metal stents [8,9,10,11,12]. Further, it has also been found that
agents released from drug-eluting stents not only affect proliferation and migration of VSMCs, but
also that of endothelial cells in in vitro [13,14], preclinical [15] as well as clinical studies [16].
Further, polymers used for designing drug-eluting stents and grafts have been associated with
hypersensitivity reactions [14-17], stenosis and thrombosis [18,19,20]. It has been observed that
endothelial cells (ECs) adhere and spread moderately on hydrophilic surfaces while EC adhesion is
reduced or even absent on hydrophobic surfaces [21,22]. Because Dacron and ePTFE polymers are
hydrophobic, they allow adsorption of adhesive proteins and adhesion of platelets with poor or no
EC adhesion. Nitinol and 316SS surfaces commonly used for designing stents have also been shown
to inhibit normal growth of endothelial cells [23].
Investigators have attempted to coat biomaterials with endothelial cells. However, the technique
has not been clinically successful due to complications associated with the isolation and seeding of
ECs in large numbers in a short time under sterile conditions and non-translatable results from
animals to humans. ECs have also been shown to display a thrombogenic profile under sub-confluent
conditions [24].
Protein-resistant surfaces have been developed by immobilizing hydrophilic molecules such as
poly(ethylene oxide) (PEO) and polyethylene glycol (PEG) on synthetic polymers [25], reducing
protein adsorption by steric repulsion and creating a hydration layer with low interfacial energy at
the surface. Although PEG-coated implants have shown significantly reduced platelet adhesion [2629], most in vivo studies of PEG-coated implants have been unsuccessful at promoting blood
coagulation and blood clot formation [30,31,29]. Various bioactive coatings such as heparin [32],
nitric oxide [33], thrombomodulin [34,35] and hirudin [36] have been proposed to prevent platelet
adhesion. However, their short half-life on a biomaterial’s surface decreases their suitability for longterm hemocompatibility. Hence, improvements of currently available systems and introduction of
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novel techniques are needed to advance towards the goal of preventing restenosis without the cost of
delayed endothelial healing and increased thrombogenicity.
Surface modification techniques such as plasma treatment are used to increase surface hydrophilicity;
however, these surfaces do not allow selective adsorption of nonadhesive albumin protein. Cellular
and platelet response largely depends on the adsorbed protein layer on the biomaterial [37-41]. The
exposure of a biomaterial to blood results in competitive adsorption of plasma proteins [42,43].
While higher levels of surface-adsorbed adhesive proteins such as fibrinogen, von Willebrand factor
and vitronectin have been shown to correlate with adhesion and aggregation of platelets[44], the
albumin layer has been shown to minimize adhesion and aggregation of platelets, thus preventing
subsequent thrombus formation [39,45-51,56]. Researchers have immobilized molecules such as
straight chain 16-18 alkyl chains, dextran, dextran-cibacron-blue (CB) dye conjugate and
monoclonal antibodies specific to albumin to generate albumin-binding surfaces[49,50,54].
However, these molecules have not been efficient in allowing the adsorption of specifically albumin
on biomaterials. Crosslinking agents such as glutaraldehyde and carbodiimide have also been
employed to bind albumin on polymers such as Dacron [55,32]. However, these crosslinking agents
have caused intense inflammatory reactions such as formation of foreign body giant cells both in
vitro and in vivo and have demonstrated short-term antithrombogenicity and hemocompatibility
properties due to rapid resorption of crosslinked albumin [56-58]. Denaturation of albumin after
adsorption has also been shown to allow adhesion of platelets because of exposure of hidden RGD
sequences [33].
In the present study, human serum albumin films were anchored on metallic substrates using poly
(glycidyl methacrylate) (PGMA). PGMA has been known for its high surface density and affinity
for reacting with amines [59]. PGMA binds HSA through a nucleophilic addition reaction that results
in the formation of strong covalent bonds with the surface. Epoxy groups of PGMA act as spacer
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molecules and bind to albumin, keeping them close to their native secondary structure conformation.
The effect of HAS on fibrinogen adsorption, human platelet adhesion and vascular smooth muscle
cells was assessed.

3.2 Materials
Nitinol (NiTi) sheet (0.25mm thick) was purchased from Johnson Matthey Inc. (Part#83975;Wayne,
PA).Using wire electrical discharge machining (EDM), 15mm diameter discs were cut from the NiTi
sheet keeping a square lip to facilitate sample handling. NiTi discs were cleaned with 100% acetone
for 20 minutes in an ultrasonic cleaner. Discs were then placed in a 1% (by vol) detergent solution
(Liquinox brand, Alconox Inc.) and ultrasonicated for another 20 minutes. The discs were then put
through three 15-minute ultrasonic rinse cycles in ultrapure de-ionized water, where the water was
completely changed after each rinse. Air-dried samples were then sterilized by a validated ethylene
oxide sterilization process according to ISO-11135-2014 [60].
Highly polished single-crystal silicon wafers (1cm x 1.2cm) were purchased from Semiconductor
Processing Co. (Boston, MA) and were used as a substrate for surface morphology and roughness
analysis. Silicon wafers and hollow glass beads of 25 mm diameter used for fibrinogen adhesion
force measurements were first cleaned in a hot (80ºC) piranha solution (3:1 conc. H2SO4: 30% H2O2)
for an hour, then in an ultrasonic bath for 30 minutes and then rinsed three times for 10 minutes with
high purity DI water and dried under a nitrogen stream. 6mm diameter silicone membranes were cut
from biomedical grade silicone sheets (SMI, 0.15” NRV G/G 40D; SimPore, NY) and used as a
control.
Human albumin (Sigma-Aldrich Corp., St. Louis, MO; CAS # 7024-90-7) (25% wt/vol) in
phosphate buffered saline was freeze dried and stored at -20C. Potassium phosphate buffer (25mM,
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pH 7.4) was prepared by combining 4:1 monobasic:dibasic salts (Sigma-Aldrich Corp., St. Louis,
MO) to maintain a pH of 7.4. Poly (glycidyl methacrylate) (PGMA) ((Polymer Source, Dorval,
QC) was prepared via free radical polymerization following the procedure of Luzinov et al. [88]. A
number-average molecular weight Mn = 58,000 g/mol and polydispersity index (PDI) =1.57 were
determined using size-exclusion chromatography (SEC) and a separations module (Waters Corp.,
Milford, MA, Alliance 2965 separations module) equipped with three PLgel 5mm MIXED-C
columns 7.5x300 mm (Polymer Labs, Amherst, MA, Part no. PL1110-6500) in series and a
refractive index detector (Waters Corp., Milford, MA, Waters Model 2414).
Differential scanning calorimetry (DSC) (TA instruments, New Castle, DE; Model 2920) was
performed to determine the denaturing temperature and safe processing temperature window of
human serum albumin at a heating rate of 20C min-1. Thermogravimetric analysis (TGA) (TA
instruments, New Castle, DE; TGA 2950) was carried out under N2 purge (40mL min-1) to study
thermal stability.

3.3. Methods and Characterization

3.3.1

Substrate coating of PGMA and HSA

Plasma treated substrates functionalized with hydroxyl groups were modified with dip-coating
(Mayer Feintechnik, Gottingen, Germany; D-3400) using a 0.5% wt/vol PGMA (Mn = 176000 g/mol)
solution in chloroform for 20 minutes followed by annealing at 110 C
̊ for 10 minutes to produce an
epoxy-rich anchoring layer. PGMA- modified substrates were dip coated with 5% wt/vol HSA in
phosphate buffer for 30 minutes, followed by annealing at 150 ̊C for 1 hour (Fig 1). PGMA-HSA
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coated substrates were rinsed in fresh phosphate buffer three times for 30 minutes to remove unbound
protein and were sterilized using ethylene oxide sterilization [88].

Figure 3.1: Schematic of the fabrication of human serum albumin film on nitinol.

3.3.2. Surface Analysis
An atomic force microscope (VECCO Probes, Santa Barbara, CA; Dimensions 3100 Atomic Force
Microscope) equipped with a NanoScope IIIa controller was used to image the morphology of the
HSA film on silicon wafers in tapping mode at different annealing times. Samples were scanned
using a silicon cantilever and silicon tips with spring constants of 50 N/m. Imaging was done at
scan rates in the range 1-2 Hz.
Swelling studies were conducted in contact mode with HSA films prepared under different annealing
times using a Multimode AFM (VECCO Probes, Santa Barbara, CA; Dimensions 3100 Atomic Force
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Microscope) with a NanoScope IIIa controller and a liquid cell and silicon nitride cantilevers
(VECCO Probes, Santa Barbara, CA; DNP-20) with a force constant of 0.24Nm-1.
Thickness measurements were made using a variable angle ellipsometer (Beaglehole Instruments,
Wellington, New Zealand), which utilizes a He-Ne laser light source (l= 632.8nm). Measurements
were conducted at integral values of incident angle ranging from 80 ̊C to 35 ̊C. The thicknesses
reported are averages of three ellipsometric measurements from selected areas near the center of a
modified silicon wafer. The refractive indices used for each layer were as follows: NPGMA=1.525,
NHSA=1.5.
The binding between PGMA and HSA was confirmed by Fourier Transform Infrared (FT-IR)
Spectroscopy using an FTIR Spectrometer (Thermo Nicolet, Walpole, MA; Continuum 6700). A
total of 16 scans at a resolution of 4 cm-1 were collected for the HSA-PGMA sample and compared
against a background collected of bare NiTi disc.
Static water contact angles were measured using sessile drop method using a Drop Shape Analyser
(Kruss Optronic, Germany; DSA10-MK2). A water droplet (1 uL) was placed onto the sample
automatically using a syringe. The contact angle values reported are averages of three drops along
the center of HSA-coated and bare-nitinol surfaces.
3.3.3 Fibrinogen Adhesion Force Measurement
The Adhesion force of fibrinogen to HSA films was examined using an AFM colloidal probe
technique (Figure 3.2). Force constant 0.093± 0.005Nm

-1

of AFM cantilevers (N-P series, Veeco

Inc.) was determined by cantilever vs. cantilever calibration method. Cleaned 20µm hollow glass
beads (as described in section 1.1) were stirred in a 1% wt/vol solution of PGMA (Mn = 170000
g/mol) in chloroform for 24 hours and rinsed three times with pure chloroform. This treatment creates
a thin (about 2nm) PGMA film on the glass surface. The beads were glued to the cantilevers, applying

66

the procedure described elsewhere [89]. Modified cantilevers were immersed in 1mg/mL solution of
human fibrinogen (FIB-3; plasminogen, von Willebrand factor, and fibronectin depleted; Enzyme
Research Laboratories, South Bend, IN) in phosphate buffer for 30 min and were rinsed in pure
buffer solution and DI water and dried at room temperature. PGMA has a high affinity to fibrinogen
and the protein is adsorbed irreversibly on the polymer’s surface. Force distance measurements were
carried out by AFM contact mode. The deflection of the cantilever with fibrinogen-coated beads on
HSA nanofilms corresponds to the adhesion force between fibrinogen and the surface. Thin films
(10-20nm) of carboxy-terminated poly(ethylene glycol) (PEG) methyl ester (P14170, Polymer
Source, Inc)[61,62] and polystyrene (PS) grafted on to a surface modified with PGMA were used as
negative and positive control, respectively.

Figure. 3.2. Schematic for measuring the adhesion force of fibrinogen to HSA films.
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3.3.4 Human Albumin Secondary Structure Confirmation
The secondary structure conformation of annealed human albumin was determined by circular
dichroism (CD) spectroscopy. Quartz slides (0.375”x 1.625” x 0.0625”, Chemglass) were cleaned in
piranha solution for 30 minutes, followed by a Radio Corporation of America (RCA) basic wash
(1:1:5 v/v NH4OH/H2O2/H2O, Sigma-Aldrich, St Louis, MO; CAS no 1336-21-6, 7722-84-1). The
slides were then rinsed with 100% ethanol (Pharmco-Aaper; Catalog No. 11100200, City, State),
followed by nanopure water and then dried under a stream of nitrogen gas. HSA films were prepared
on quartz slides as described in 2.1. CD spectropolarimetry was performed using a JascoJ-810
spectropolarimeter (Jasco, Inc., Easton, MD) to determine the native and adsorbed secondary
structures of human albumin. High transparency quartz cuvettes (Starna Cells, Inc., Atascadero, CA)
were used for determining the native solution structure while the adsorbed structure of HSA on quartz
slides was determined using a cuvette custom-designed [63] for maximizing signal-to-noise-ratio.
The CD spectra (molar ellipticity vs. wavelength) obtained were deconvoluted using the sp22x
algorithm and analyzed using the SELCON and CONTIN/LL software packages [90] to quantify the
percentage of alpha-helix and beta-sheet content of native/adsorbed protein.

3.2.5 Fibrinogen adsorption
Human plasma fibrinogen fluorescently labeled with rhodamine-NHS dye ester (CAS no. 135280917-6, Sigma-Aldrich, St. Louis, MO) was dialyzed for 48 hours to remove unbound dye. Labeled
human fibrinogen was incubated on HSA films coated on NiTi discs along with controls for 1 hour
at 37ºC with gentle shaking. Fluorescence was measured at excitation-emission wavelengths of 575
and 525nm.
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3.2.6 Human Platelet Isolation and Adhesion
Platelet rich plasma (PRP) from fresh human blood was isolated by centrifuging the acid-citrated
dextrose (ACD) anticoagulated blood (225g, 15 min, 25C) using a Beckman Coulter Allegra 6R
centrifuge (Beckman Coulter, Fullerton , CA). All protocols for participation of human blood donors
were approved by the Institutional Review Board at Clemson University. Platelet concentration was
measured using a Beckman Coulter Z2 Particle count and size analyzer (Bechman Coulter, Fullerton,
CA). The platelet concentration was adjusted to 106 platelets/mL with platelet suspension buffer
(137mM NaCl, 2.7mM KCl, 5.5mM Dextrose, 0.4 mM sodium phosphate monobasic, 10 mM
HEPES and 0.1U/ml apyrase)[84]. Platelet suspension buffer was added with 2.5 mM CaCl 2 and
1.0mM MgCl2 to add metal ions. The platelet solution was allowed to rest for 30 minutes at 37ºC
before being added to the HSA coated and the uncoated disc controls in a 24 well and then allowed
to adhere for 1 hour at 37ºC under static or shear condition. At the end of platelet adhesion time, the
suspension was aspirated from each well, and each well was rinsed with phosphate buffer to remove
unbound platelets. Orbital shear was provided using an orbital plate shaker (VWR, S-500) calculated
using the following equation,
Τmax = a √ ηρ (2πf)3
(a- radius of gyration of the shaker (cm), ρ- density of solution (g/mL), η- viscosity at 37°C (poise)
and f- frequency of rotation (rps)). Frequency of 250 rpm, as per the above equation corresponded to
a maximal shear stress of 12.7 dynes/cm2, comparable to arterial shear levels.
Platelet adhesion was quantified by measuring the lactate dehydrogenase (LDH) released when
adherent platelets were lysed with Triton-PSB buffer (2% v/v Triton-X-100 in PSB), using a CytoTox
96® Non-Radioactive Cytotoxicity Assay (Promega Corporation, Madison, WI). Absorbance was
measured at 490nm using a UV/Vis spectrophotometer (Bio-Tek Instruments Inc.,Vinooski,
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Vermont). A calibration curve was constructed with known number of platelets, counted using a
Beckman Coulter Z2 Particle Count and Size Analyser (Beckman Coulter, Fullerton, CA), and the
platelet adhesion on the HSA films were determined using the calibration curve.
3.2.7 Bioactivity of Vascular Smooth Muscle Cells (VSMCs)
Using an approved protocol by Clemson University Institutional Animal Care and Use Committee,
abdominal aortas were harvested from 6-10 weeks old female Sprague-Dawley rats. Adventitia, fat
layers and endothelium were removed. VSMCs were isolated from the vascular medium using
collagenase type II (Worthington, Biomedical, Lakewood, NJ) and elastase (Worthington
Biomedical, Lakewood, NJ) [64]. The cells were maintained in Dulbecco’s modification of Eagle
Medium (DMEM, 10-013-CV; Mediumtech, Herndon, VA) supplemented with 10% heatinactivated fetal bovine serum (FBS) (F-4135; Sigma-Aldrich, St. Louis, MO) and 1% antibioticantimycotic (A5955, Sigma-Aldrich, St. Louis, MO) under standard cell culture conditions (37C,
5%CO2, 95% relative humidity).
Experiments were carried out using VSMCs between passages 4-8. For experimental testing, cells
were trypsinized using 0.25% trypsin containing 0.2mg/mL EDTA (Sigma Chemical Company,
E6511, St. Louis, MO, USA).
The experiment was divided into HSA films and bare NiTi experimental groups, and polystyrene
(PS) surfaces served as the control (N=4 samples/group). Cells were cultured for 5 days, 15 days and
30 days. After each time period, the culture medium was removed, and the cells were evaluated using
the test methods described below.
3.2.8 Characterization of Smooth Muscle Cells
Smooth muscle cells were characterized by immunofluorescent staining for contractile markers
smooth muscle α-actin (SM α-actin) and calponin. VSMCs were fixed with cold 4% formaldehyde

70

and blocked for 45 minutes at room temperature with a blocking solution that consisted of 40mg/ml
bovine serum albumin in PBS, 6% FBS, and 0.05% Triton-X. Cells were then treated with primary
mouse anti-α-actin antibody (Abcam) and primary rabbit monoclonal anti-calponin antibody, both
diluted 1:500 overnight at 4C. Cells were then treated with fluorescent tagged goat anti-mouse
secondary antibody and goat anti-rabbit secondary antibody, both diluted 1:200 in the blocking
solution, for 3 hours respectively at room temperature. The cells were then stained with DAPI
(Molecular Probes, D-1306, Eugene, OR) and imaged using fluorescent microscopy (Nikon LVUDM, Nikon Instruments Inc., Melville, NY).
3.2.9 Cell Morphology
After each time period, culture medium was removed, and cells were fixed in 4% paraformaldehyde
solution for 20 minutes. Cells were then permeabilized using 0.25% Triton-X detergent in phosphate
buffer for 10 minutes. The cytoskeletal F-actin and cell nuclei were stained using 25 μg/ml
rhodamine-phalloidin (Invitrogen, R415) and by 4’, 6-diamidino-2-phenylindole (DAPI) (Molecular
Probes, D-1306, Eugene, OR) respectively. The cells were then imaged using fluorescent microscopy
(Nikon Inc., Diaphot 30).
3.2.10 Cell proliferation
VSMC proliferation was analyzed using a methylthiazol tetrazolium (MTT) (Sigma-Aldrich, MO,
USA) assay after 24 hours. A total of 3-(4,5-dimethylthiazol -2-YL)-2,5-diphenyltetrazolium
bromide was dissolved in 1x DPBS at a concentration of 2mg/mL. VSMCs were rinsed with 1x
DPBS and then placed in 1mL DMEM solution with no FBS. A total of 240 μl of MTT was added
to the well, and the solution was incubated for 4 hours. After incubation, the MTT-DMEM solution
was removed and 1mL of DMSO was added to the well. Using a plate reader, absorbance was then
read at 570nm.
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3.2.11 Expression of alpha-actin
α-actin expression in smooth muscle cells cultured on HSA, bare NiTi and PS surfaces was analyzed
using a modified cell-based ELISA assay [65]. Briefly, at indicated times, the medium was removed,
and the cells were fixed in cold methanol. They were then incubated with a blocking solution that
consisted of 40mg/ml bovine serum albumin in PBS, 6% FBS, and 0.05% Triton-X for 45 minutes
at room temperature. Primary mouse anti-α-actin antibody diluted 1:200 in the blocking solution was
then added to the metal discs for 2 hours at room temperature followed by a 2hr treatment with biotin
conjugated bovine anti-mouse IgG, also diluted 1:200 in the blocking solution. After extensive
washing, the cells were incubated with horseradish peroxidase (HRP) conjugated anti-mouse
secondary antibody. Chromogenic substrate (3 mM p-nitrophenyl phosphate, 0.05 M Na2CO3, and
0.05 mM MgCl2) was then applied to produce color, and the absorbance was read at 405 nm with a
microplate reader (Beckman Instruments, Inc., DTX 880, Fullerton, CA). The cells were then DAPI
stained and imaged to facilitate cell counting. Lastly, absorbance due to nonspecific binding was
subtracted from that of the experimental groups, with the net absorbance normalized against cell
count on each disc giving a number directly related to the α-actin content per cell.
3.2.12 Adhesion Strength of HSA coating

Adhesion strength of HSA coating on NiTi discs was evaluated by ASTM D1002 procedure [91].
An HSA-coated NiTi disc was attached to bare NiTi disc using an epoxy glue. A dynamometer
(Instron 4204), to which the NiTi discs were glued, was used to calculate the failure load and
displacement of the interfaces. The tests were performed with a 1kN load cell and cross bar speed of
1.3mm/min. The load measured at the moment of detachment was divided by the adhesion overlap
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surface between metal and protein film to obtain shear stress value. Presence of HSA film after
displacement of interfaces was assessed by FT-IR spectroscopy.
3.2.13 Degradation of HSA film
HSA-coated discs were immersed in phosphate buffer in an orbital shaker maintained at 37°C with
a rotation of 250rpm (N=5) for 120 days. The buffer was collected to measure the HSA released from
the discs using a bicinchoninic acid (BCA) test for protein estimation.
3.2.14 Statistical Analysis
The results presented are the mean values with 95% confidence intervals (CI). The statistical
significance of differences between mean values for different samples and conditions was evaluated
using a student’s t-test, with p ≤ 0.05 considered as statistically significant.
3.3 Results
3.3.1 Thermal Analysis

The DSC thermogram in Figure 3.3a indicates that the human albumin protein denatures at a
temperature of 130–150°C. However, this temperature is clearly not the protein degradation
temperature, which begins around 220°C, as observed in the TGA thermogram in Figure 3.3b
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Figure 3.3. a) Differential scanning Calorimetry (DSC) thermogram of human serum albumin
powder. b) Thermogravimetric analysis (TGA) of human serum albumin powder.

3.3.2 Surface Roughness Analysis
Figure 3.4 shows the surface morphology and roughness of HSA annealed at 150°C for an hour. The
average roughness of the HSA layer is 0.307±0.07nm. The morphology and roughness values
indicate a homogeneous and smooth surface of HSA films.

Figure 3.4. Surface morphology and surface roughness value of human serum albumin (HSA)
assessed by atomic force microscopy.
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3.3.3 Fourier Transform Infrared (FT-IR) Spectroscopy
Binding between PGMA and HSA on nitinol surface was confirmed using FT-IR spectroscopy as
shown in Figure 3.5.

Figure 3.5: IR spectra of HSA and PGMA with characteristic carbonyl and amide bonds.

3.3.4 Circular Dichroism (CD) Spectroscopy
A 15.3% decrease in the α-helix secondary structure was observed for annealed albumin as compared
to its native form (Figure 3.6). HSA films showed a significant decrease in the adsorption of
fluorescently labeled human fibrinogen as compared to NiTi (p= 0.023).
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Figure 3.7: Adsorption of fluorescently labeled human fibrinogen on different surfaces.
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3.3.5 Adhesion Force measurement of fibrinogen
As shown in Figure 3.8, a minimal adhesion force 0.3±0.1nN/m (mean±SD; N=50 points) between
fibrinogen and human serum albumin film was observed using AFM as compared to adhesion of
fibrinogen and PGMA surfaces fibrinogen and silicone used as a negative control.
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Figure 3.8: Adhesion force measurement between human fibrinogen and different surfaces using
AFM colloidal probe microscopy.

3.3.6 Human Platelet Adhesion
HSA films allowed 6.54±3.3% platelet adhesion under static conditions and 4.59±2.4% adhesion
under shear conditions (12dynes/cm2) significantly less than NiTi under static (32.3% adhesion) (pvalue =0.014) and shear (21.7% adhesion)(p-value = 0.021) conditions (Fig. 3.9).
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Figure 3.9: Assessment of adhesion of human platelets on HSA, NiTi and PS surfaces under static
and shear conditions.
3.3.7 Smooth muscle cell characterization, proliferation, phenotype and morphology
Smooth muscle cells were characterized for F-actin fibers by Rhodamine-Phalloidin staining and for
contractile markers α-actin and calponin by immunofluorescent staining. HSA films allowed
significantly less proliferation of rat aortic smooth muscle cells, assessed over a period of 5, 15 and
30 days compared to bare NiTi (p-value 0.027, p-value 0.031, and p-value 0.032 respectively)
assessed by MTT cell proliferation test (Fig.11). MTT dye (yellow color) was reduced to formazon
dye (purple color) by active reductase enzymes, thus permitting quantification of the metabolically
active, healthy and proliferating cells (materials cytotoxicity) via colorimetric measurements. The
cell-based ELISA assay developed for this application resulted in a number directly proportional to
smooth muscle α-actin content per cell.
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Figure 3.10: MTT cell proliferation assay for assessment of smooth muscle cell viability and
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15 and 30 days. * represents p<0.05 compared to NiTi.
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Rhodamine-phalloidin staining demonstrates more elongated and spindle-shaped morphology of
VSMCs cultured on HSA films as compared to NiTi and PS surfaces assessed by confocal
microscopy.

DAY 1

DAY 15

DAY 30

HSA

NiTi

PS

Figure 3.12: Rhodamine-phalloidin staining of rat aortic vascular smooth muscle cells cultured on
HSA, bare NiTi and PS surfaces. Red: F-actin; Blue: Cell nuclei: 10X; Bar represents 400 µm.
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3.3.8 Adhesion Strength of HSA film
The presence of albumin film sheared at 5.48MPa was confirmed by FT-IR spectroscopy. Albumin
film on a nitinol surface after application of shear stress, which is three times the stress applied during
a balloon angioplasty procedure (~2.02MPa) [92,93], confirms the strong binding of the albumin
film on the surface.
Max load (N)

True Strain at maximum load

True stress at maximum load (MPa)

(mm/mm)
525.575

0.1017

5.48

Table 3.1: Strain and stress values obtained after application of load on albumin coated NiTi.
3.3.9 Degradation of HSA film
HSA covalently bound to PGMA was fully degraded in 120 days from the NiTi surface in phosphate
buffer subjected to a rotation of 250 rpm, equivalent to a flow shear of 12.7 dynes/cm2.
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Figure 3.13. In-vitro degradation of HSA film from nitinol surface.
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3.4 Discussion
This study highlights the potential of HSA as a coating to mitigate the complications of inherent
thrombogenicity and smooth muscle hyperplasia. After decades of research on hemocompatibility
and intimal hyperplasia, thrombosis and restenosis remain two major complications resulting in
failure of endovascular stents. Polymers used in designing stents increase the incidence of thrombus
formation by providing a surface for adhesion and aggregation of platelets [18-20] Drugs used in
drug-eluting stents for controlling smooth muscle cell proliferation delay re-endothelialization,
which is essential as a barrier between the vessel lining and blood components [66]. Therefore, a
successful endovascular device must be designed to prevent adhesion of platelets and hyperplasia of
smooth muscle cells without delaying healing. In this study, we developed a method for coating
substrates with human serum albumin using PGMA as an anchoring layer.
Human serum albumin is the most abundant protein present in our blood. It has been shown to
passivate material surfaces, thus blocking sites for adsorption of other proteins and adhesion of
platelets and cells [39,45-51]. PGMA was used to form a reactive anchoring polymer layer. A
polymer with epoxy functionality was chosen, since the reactions of epoxy groups are quite universal
and can covalently anchor PGMA to the substrate surface [67]. The glycidyl methacrylate units
located in the “loops” and “tails” sections of the attached PGMA chain could serve as reactive sites
for the subsequent attachment of (macro) molecules with complementary functional groups. PGMA
is also known for its high surface density and affinity for reacting with amines [68].
The advantageous aspect of covalent immobilization is the ability to provide a stable bond between
the biomolecule and the functionalized polymer. Covalent bonding ensures integrity of the layer,
promoting prolonged and/or continuous activity of implanted devices.
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Binding between PGMA and HSA was confirmed by FTIR spectroscopy. From the IR results, the
presence of a peak at 1720cm-1 depicting C=O stretch in PGMA, an amide I peak at 1650cm-1 and
amide II bond peaks at 1540 cm -1 in HSA on the surface confirmed that HSA binds to the PGMA
anchoring layer. Smooth and homogeneous surface morphology of the HSA layer was studied
using atomic force microscopy. For cardiovascular application, a smooth device surface coating
can significantly decrease injury to blood vessels. In addition, surface roughness is often correlated
to cell adhesion and migration and, in particular, to human endothelial cells growth [68,69].
Furthermore, a smooth stent surface is believed to reduce platelet activation and aggregation,
consequently leading to less thrombus formation and neo-intimal proliferation [70]. The
developed-coating stent showed a reduced surface roughness when compared to bare metal stents,
even in dry conditions, that could lead to less vascular injury at the moment of angioplasty
procedures.

Dry layer thicknesses of PGMA and HSA films on silicon wafers measured by ellipsometry were
26±3.2 and 92±9.6nm respectively. In agreement with results from Zdyrko et al. [71], a static water
contact angle of 60±2.3º was measured for PGMA on the silicon surfaces. When an epoxy group
reacts with a primary amine, a secondary amine and secondary alcohol are formed. HSA binding to
PGMA increased the thickness of the surface layer, which suggests that primary amines readily
penetrate and react throughout the PGMA film. A water contact angle of 66º was measured for the
HSA layer bound to PGMA, which is consistent with the value of 62º reported for the water contact
angle of amines [72].
A notable correlation between the secondary structure conformation of albumin and adherence of
platelets has been studied. Beyond a critical point of unfolding (>34%), human albumin has been
shown to undergo a change in structural orientation facilitating adhesion of platelets on albumin even
though it has no amino acid sequences to bind to platelet receptors [33]. PGMA has been used as an
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anchoring layer because it has epoxy groups that immobilize and stabilize protein molecules by
preventing their surface-adsorbed denaturation [73]. Change in the secondary structure conformation
of annealed albumin was studied by CD spectroscopy. A 15.3% decrease in the alpha-helix content
of the annealed albumin depicted that HSA covalently bound to PGMA retained most of its native
secondary structure conformation.

Shear strength of HSA coating on NiTi was assessed by ASTM D1002. Scanning electron
microscopy was used to evaluate the integrity of HSA film after stent expansion. HSA coating
appeared to be uniform over the entire length of the stent after application of strain. No cracks in
the HSA coating were found along the length of the stent. The presence of Nitrogen on the surface
after strain application by EDX spectroscopy confirmed the presence of HSA on the stent surface.
Coating ruptures and cracks have been proved to facilitate restenosis and thrombogenic events. If
the stent has webbings and bridges between the struts, the coating may break off from the stent
when the stent is dilated by a balloon catheter during the deployment, and thrombus and vascular
smooth muscle cell (VSMC) proliferation can occur at the site where the coating breaks off [85].

Fibrinogen adsorption and platelet adhesion are considered to be major processes dictating
hemocompatibility of a biomaterial. In our study, we measured the adsorption of fluorescently
labeled fibrinogen on HSA films. Significantly less adsorption of fibrinogen occurred on HSA films
as compared to bare NiTi (p -value 0.023). The number of platelets adhered to different surfaces was
quantified by measuring LDH activity. The sensitivity and reliability of the LDH method has been
confirmed by researchers, revealing a linear correlation between LDH activity and platelet number
[86,87]. Platelets are activated by a foreign stent material and the artery wall gets denuded of
endothelial layer post-surgery [74]. Thus, stent implantation or vascular graft surgery results in a
highly prothrombotic surface exposed to the blood stream. Stent struts are covered with thrombus
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within a few hours or days following implantation. Previous studies on the thrombogenicity of
polymeric arterial graft materials have demonstrated high platelet deposition on these surfaces
immediately after implantation [18-20]. In vitro biocompatibility studies have revealed that albumincoated surfaces substantially decrease the platelet adhesion and activation of an untreated or preclotted polyester graft [56,57]. An in vivo study by Rumisek et al. [58] demonstrated that an
albuminated graft implanted in the canine iliofemoral artery allowed fewer platelets to adhere in the
first 3-days compared to the pre-clotted polyester control. We measured platelet adhesion under static
and shear conditions since thrombus formation in vivo occurs under flow conditions. An orbital
shaker system was used to study influence of shear on platelet interactions with the substrate [75,76].
Requiring low volumes of platelet suspension, the setup was used to model disturbed flow patterns
in vivo. Our results confirm the earlier findings and show that a significantly lower number of
platelets adhered on HSA films as compared to bare NiTi in static (p-value 0.014) and shear
conditions (p-value 0.021).
Prevention of early thrombosis by anti-thrombogenic therapies does not guarantee long-term vessel
patency [77]. The need for an anti-thrombogenic therapy that can prevent the incidence of thrombosis
long-term is imperative. We found the HSA film covalently bound to PGMA with slow degradation
in in vitro conditions. Although we have not reported the long-term effect of the HSA film on
adhesion of platelets, we have measured strong binding of HSA film for 120 days rendering an antithrombogenic surface facilitating long-term patency of vascular devices.
Contractile smooth muscle cells are characterized by low cell proliferation, elongated spindle-shaped
morphology, and high expression of contractile markers such as α-actin. These three characteristics
of smooth muscle cells cultured on HSA were evaluated and compared against cells grown on bare
NiTi. A possible explanation for low proliferation of smooth muscle cells on HSA films could be
that HSA does not allow adsorption of other proteins such as fibronectin, which has been shown to
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be important in cell adhesion, ECM synthesis and proliferation [82]. F-actin staining of smooth
muscle cells by rhodamine-phalloidin and DAPI revealed that VSMC cultured on HSA films
exhibited a more elongated and spindle-shaped morphology, an indication of a contractile state. An
elongated smooth muscle cell morphology decreases SMC proliferation [83]. To quantitatively
assess the contractile state of VSMCs, a cell based ELISA assay was performed to measure the
expression of contractile marker smooth muscle alpha-actin. At Day 5, VSMCs cultured on NiTi
exhibited higher amounts of alpha actin as compared to HSA. However, at Day 15 and Day 30,
smooth muscle alpha actin content on VSMCs cultured on NiTi decreased, and the actin content of
VSMCs cultured on HSA increased. Although the difference was insignificant at Day 15 (p-value
=0.063), at Day 30 the alpha-actin content of VSMCs cultured on NiTi significantly decreased as
compared to HSA (p-value = 0.038). Contractile healthy smooth muscle cells are characterized by
low proliferation, elongated and spindle-shaped morphology and high expression of contractile
markers. Nickel ions from nitinol cause decrease in alpha-actin expression of smooth muscle cells
[78-81]. HSA film on nitinol surfaces significantly reduces the proliferation and maintains the
contractile state of vascular smooth muscle cells.
This study has demonstrated the potential of human serum albumin as a vascular-device coating for
metallic biomaterials by shielding the adsorption of adhesive proteins such as fibrinogen and
preventing the adhesion of platelets. Human albumin, because of its anti-adhesive and surface
passivating effects, has the potential to control the proliferation of smooth muscle cells and maintain
their contractile phenotype, possibly obviating the need for an anti-proliferative drug. Thus, HSA
coating could be used for endovascular stents and grafts for its potential to prevent the incidence of
thrombosis and intimal hyperplasia.
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3.5 Conclusions
In this study, a novel procedure to bind human albumin on substrates using PGMA as an anchoring
layer is designed to impart hemocompatibility to materials by preventing fibrinogen adsorption and
platelet adhesion. In parallel, human albumin coating described in this research can control the
complications of neo-intimal hyperplasia by maintaining low proliferation and contractile expression
of smooth muscle cells, thus validating its potential as a vascular-device coating. The efficacy of this
coating to accelerate endothelialization of vascular grafts would be the focus of further work.
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CHAPTER 4
ASSESSMENT OF POTENTIAL OF HUMAN ALBUMIN TO MITIGATE THE INCIDENCE OF
THROMBOSIS AND INTIMAL HYPERPLASIA UNDER PHYSIOLOGICALLY RELEVANT
FLOW SHEAR CONDISTIONS.

Abstract: Synthetic graft prostheses such as ePTFE have shown significantly low clinical patency
rates as compared to autogenous vessel substitutes such as saphenous vein and internal mammary
artery. Intimal hyperplasia and thrombosis remain the major obstacles to the development and
application of synthetic conduits. Surface modification strategies to alter surface properties of ePTFE
are imperative to enhance its biocompatibility. Our proposed study examined the potential of a
human albumin film on ePTFE for enhanced hemocompatibility and adhesion strength. Human
albumin film prevents adsorption of adhesive human fibrinogen protein, evidenced by experiments
with fluorescently labeled human fibrinogen and adhesion force measurements using atomic force
microscopy. In physiological conditions, biodegradation of human albumin from the ePTFE surface
shows the film’s high adhesion strength. Human albumin coating on ePTFE does not affect the
material’s superior mechanical property of longitudinal tensile strength. Human albumin film shows
significantly less human platelet adhesion on the surface as compared to bare ePTFE, making human
albumin film a potential vascular coating for enhanced hemocompatibility with strong adhesion
strength. In a platelet-smooth muscle cell co-culture model, smooth muscle cells exhibited controlled
proliferation and increased contractile protein expression on albumin coated ePTFE material as
compared to bare ePTFE.
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4.1 Introduction
Autologous vessels, by reducing the incidence of thrombosis and restenosis, remain the gold standard
for bypass graft surgeries. The standard is challenged, however, by the unavailability of healthy
autologous arteries. Synthetic polymers have been widely employed in fabricating vascular grafts,
offering the advantages of biocompatibility and stability in biological environments. However, they
have shown poor clinical outcomes for small-diameter vessel replacement because of high rates of
thrombosis in low flow environments [1-3]. The synthetic surface of the graft material is associated
with a high thrombogenicity and increased intimal hyperplasia [4-6].
Blood-biomaterial interactions play a major role in facilitating a thrombotic response. Upon
implantation, the surface of a biomaterial is rapidly encapsulated by an adsorbed protein layer that
triggers the activation, adhesion and aggregation of platelets and activation of the coagulation
cascade, resulting in the formation of a thrombus on the surface [7-9]. The biomaterial can activate
the complement system, resulting in an inflammatory response [10]. Thus, the biomaterial surface
and the adsorbed protein layer become an important determinant of biocompatibility and long-term
success.
Expanded-polytetrafluoroethylene (ePTFE) has been widely used in a variety of applications due to
its excellent chemical stability and mechanical properties. However, due to its highly hydrophobic
nature, ePTFE has been shown to allow adsorption of adhesive proteins [11], which facilitates
adhesion of platelets contributing to higher incidence of thrombosis [12,13]. The inert nature of
ePTFE prevents the growth of vascular cells, particularly endothelial cells, further increasing the
surface’s propensity to attract platelets and increasing thrombogenicity [14,15]. Due to chemical
resistance of ePTFE, functionalization with other groups to alter biocompatibility is also challenging.
Thus, surface modification strategies to introduce new functional groups to ePTFE becomes
imperative to make it an ideal material with high strength and biocompatibility.
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Several approaches have been employed to improve long term patency of synthetic grafts [18-21].
Unmodified small diameter ePTFE grafts exposed to blood flow have shown adsorption of
fibrinogen and gamma-globulin and subsequent platelet adherence and thrombus formation in a
canine model. Covalently grafted molecules such as heparin and prostacyclin have been employed
to prevent the incidence of thrombosis [16,17]. However, these attempts failed because of shortterm retention of the molecules on the surface and difficulty in covalent binding on the chemically
stable ePTFE surface. The heparin-bonded Propaten vascular grafts designed by W.L. Gore and
Associates using Carmeda Bioactive Surface modification [22,23] have shown promising results
for lower extremity bypass with lesser rates of thrombosis [24,25]; however, the clinical trials are
nonrandomized and retrospective, which brings into question the significance of the results.
Injury due to a percutaneous coronary interventional procedure (PCI) causes endothelial
denudation, exposing smooth muscle cells to growth factors. This promotes a phenotypic shift in
the morphology of smooth muscle cells from contractile to synthetic with increased proliferation
and migration from the medial layer to the neointimal layer and increased extracellular matrix
formation [26]. Phenotypic modulation has been considered to be a key factor responsible for
progression of neointimal hyperplasia and restenosis. Hemodynamic factors such as wall shear
stress and cyclic strain from blood flow control the phenotype and function of vascular smooth
muscle cells [27]. Physiological levels of cyclic strain promote quiescent, contractile morphology
of smooth muscle cells [28], whereas high levels promote SMC proliferation and dedifferentiation
[29-31]. Endothelial denudation or VSMC migration causes exposure of the later to blood flow
[27]. Shear stress have been known to have a direct effect on smooth muscle cell proliferation with
physiological shear stress reducing proliferation and maintaining contractile morphology [32-33]
and low shear stress conditions in small diameter blood vessels and grafts promoting smooth
muscle cell proliferation and synthetic phenotype [63] and with upregulation of growth factors such
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as PDGF [35]. In vivo and clinical studies have demonstrated the occurrence of thicker neointima
under low wall shear stress [36-37].
The proposed technology involves coating ePTFE with a human serum albumin (HSA) film using
poly(glycidyl methacrylate) (PGMA), an anchoring layer, to improve cellular and blood
compatibility under low flow shear stress conditions. HSA exhibits a strong binding strength to
ePTFE with an enhanced shield to fibrinogen adsorption and platelet adhesion. Vascular smooth
muscle cells cultured on albumin coated ePTFE retained controlled proliferation and contractile state
mitigating the complication of restenosis.

4.2. Materials and Methods
4.2.1 Cleaning and Sterilization of ePTFE grafts: ePTFE (Gore-Tex, W.L. Gore and Associates,
Inc.) sheet was cleaned in 1% liquinox (vol/vol) detergent solution for 30 minutes and DI water for
30 minutes in an ultrasonic cleaner. The cleaned ePTFE discs were sterilized in an autoclave at 121 C
̊
for 1 hour.

4.2.2 Fabrication of Human Serum Albumin (HSA) film: ePTFE discs are air plasma treated
(6.8W for 10 minutes) for functionalization with hydroxyl, carbonyl, carboxyl groups and nitroxide
groups. Functionalized ePTFE surface was modified with 0.5% wt/vol PGMA (Polymer Source,
Dorval, QC) (Mn =176000 g/mol) in chloroform to produce an epoxy-rich anchoring layer followed
by dip-coating in 5% wt/vol HSA (Sigma-Aldrich Corp., St. Louis, MO; CAS # 7024-90-7) solution.
HSA adsorbed ePTFE samples were then annealed at 150 ̊C in a vacuum oven for 1 hour (Figure
4.1) [55] followed by sterilization using standard procedure of ethylene oxide sterilization ISO11135-2014 [56].
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Figure 4.1: Schematic of fabrication of human albumin coating on ePTFE surface.

4.2.3 Fourier-transform Infrared (FTIR) Attenuated Total Reflectance (ATR) spectroscopy:
The binding between PGMA and HSA was confirmed by ATR-FTIR spectroscopy (Nicolet SX-60
FTIR spectrometer) performed to collect IR spectra for albumin protein, PGMA and albumin-PGMA
coated ePTFE surface pressed on a diamond crystal stage. Absorption spectra over the range 4004000cm-1 was collected at a resolution of 8 with 128 scans using OMNIC software (Thermo Fisher
Scientific Inc., UK).
4.2.4 Adhesion strength measurement of albumin film by tensile testing: Tensile strength of
albumin coated ePTFE and bare ePTFE was measured to assess the effect of albumin coating on
ePTFE. HSA and bare ePTFE graft material samples (length 30mm, thickness 1mm, width 14mm)
were elongated at a cross-head speed of 10mm/min, and tensile force was measured using a 100N
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load cell in static and fluid state (phosphate buffer, 37°C, pH 7.4) conditions. Binding of HSA film
on ePTFE material was assessed using Energy Dispersive X-ray spectroscopy (EDX) at 20Kv to
assess the elemental composition of albumin coated ePTFE after longitudinal tensile force
application as described below following SEM preparation.

4.2.5 Scanning Electron Microscopy (SEM): Scanning electron microscopy SEM (SU-6600,
Hitachi-HTA, Inc.) was used to investigate the morphology of albumin coated and bare ePTFE grafts.
Prior to imaging, the samples were cut into 1cm x 1cm pieces and coated with a 10nm layer of
platinum to make them electrically conducive. SEM measurements were performed at an
accelerating voltage of 5.0kv and a working distance 10.6mm. A set of three images at 250x, 500x
and 1000x were taken for each sample.

4.2.6 Surface Wettability: Measurement of static water contact angle (goniometer model 260-F4VWR) between albumin-coated and bare ePTFE surface and DI water was collected using the sessile
drop method. A water droplet (5-10µL) is dispensed onto the sample from a syringe, and
measurements are recorded after 30 seconds. The contact angle values reported are averages of three
drops along the center of HSA-coated and bare ePTFE surfaces.
4.2.7 Thermal analysis by Thermo-gravimetric analysis (TGA): The degradation temperatures of
human albumin coated and uncoated ePTFE were determined using thermo-gravimetric analysis (TA
instruments, New Castle, DE; TGA 2950) by heating a 5-15mg sample on a clean platinum pan at a
heating rate of 10°C/min under nitrogen.

4.2.8 Fluorescent labeling of albumin: Human albumin (1mg/mL in phosphate buffer) was labeled
with 4µg of Alexa Fluor 488 fluorescent dye (CAS no. 1352809-17-6, Sigma-Aldrich, St. Louis,
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MO) in 200µL of dimethylformamide (DMF) and dialyzed for 48 hours to remove the unbound dye.
Fluorescently labeled albumin was adsorbed on PGMA modified ePTFE samples (10mm thick and
45mm long) and submerged in phosphate buffer in an orbital shaker to qualitatively assess the
presence of albumin on the surface using a fluorescent microscope for a period of up to 3 months.

4.2.9 Albumin release quantification: Albumin coated ePTFE discs were immersed in phosphate
buffer solution at 37°C in an orbital shaker for a period of up to 4 months at a frequency of 220rpm.
The albumin released was quantified using Bradford assay. A standard curve was created using
several dilutions (25µl, 75µl, 200µl, 400µl and 800µl) of albumin in phosphate buffer mixed with
200µL of Bradford reagent. The albumin concentration in each sample was assessed by measuring
and extrapolating absorbance at 670nm on the standard curve.

4.2.10 Fibrinogen adhesion force measurements: The adhesion force of human fibrinogen (FIB3; plasminogen, von Willebrand factor, and fibronectin depleted; Enzyme Research Laboratories,
South Bend, IN) to HSA films was examined using AFM (VECCO Probes, Santa Barbara, CA;
Dimensions 3100 Atomic Force Microscope) colloidal probe technique (Figure. 4.2). Hollow glass
beads (25µm) were cleaned in piranha solution (3:1 solution of concentrated sulphuric
acid/30%hydrogen peroxide) for 1 hour and in DI water for 30 minutes each. 20-30µm hollow glass
beads (Potters Industries Inc. Valley Forge, PA) are modified in 0.5% wt/vol PGMA (Mn = 76,000
g/mol) in methylethyl ketone (MEK) overnight and rinsed with pure MEK for 30 minutes. Modified
beads were glued to cantilevers using a protocol described by Jones and collaborators [36]. Modified
cantilevers were immersed in freshly prepared 1mg/mL fibrinogen solution in phosphate buffer for
30 minutes and rinsed in pure buffer before performing the adhesion experiment on albumin films.
The deflection (force) of a cantilever bound with fibrinogen-adsorbed bead on albumin coated and
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uncoated ePTFE corresponds to the adhesion force between fibrinogen and the surface. Forcedistance measurements were carried out by AFM contact mode.

Figure 4.2: Schematic of the procedure to measure adhesion force between human fibrinogen and
human albumin coated ePTFE and bare ePTFE surface.
4.2.11 Fluorescent labeling of fibrinogen: Human plasma fibrinogen (1mg/mL in phosphate buffer)
was fluorescently labeled with labeled with 4µg Rhodamine-NHS dye in 200µL of
dimethylformamide (Fisher) and dialyzed for 48 hours to remove unbound dye. Labeled human
fibrinogen [105] is incubated on HSA coated and uncoated ePTFE samples (15mm diameter and
10mm thick) with polystyrene controls for 1 hour at 37°C in an orbital shaker. Fluorescence was
measured at 575 and 525nm wavelengths to quantify and compare the adsorption of fluorescently
labeled fibrinogen.
4.2.12 Human Platelet Isolation and Adhesion: Heparin anticoagulated fresh human blood was
centrifuged (225g, 15 min, 25°C) to obtain platelet-rich plasma using a Beckman Coulter Allegra
centrifuge (Beckman Coulter, Fullerton, CA). All protocols for participation of human volunteers for
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blood isolation were approved by the Institutional Review Board (IRB) at Clemson University. A
platelet concentration of 106 platelets/mL in platelet suspension buffer (137mM NaCl, 2.7mM KCl,
5.5mM Dextrose, 0.4 mM sodium phosphate monobasic, 10 mM HEPES and 0.1U/ml apyrase) was
used. Platelet suspension buffer was added with 2.5 mM CaCl2 and 1.0mM MgCl2 for activation of
platelets.
The platelet solution was allowed to rest for 30 minutes at 37°C before being added to the HSA
coated ePTFE and the uncoated ePTFE controls in a 24-well plate and then incubated for 1 hour at
37°C under static and shear conditions. At the end of the 5-day incubation period, the suspension
was aspirated from each well, and each well was rinsed with phosphate buffer to remove unbound
platelets. Orbital shear was provided using an orbital plate shaker (VWR, S-500) calculated using
the following equation,
Τmax = a √ ηρ (2πf)3
where, a- radius of gyration of the shaker (cm), ρ- density of solution (g/mL), η- viscosity at 37°C
(poise) and f- frequency of rotation (rps)). A frequency of 60rpm, as per the above equation,
corresponded to a shear stress of 1.2dynes/cm2 respectively, comparable to arterial low flow shear
levels.
Platelet adhesion was quantified by measuring the lactate dehydrogenase (LDH) released when
adherent platelets were lysed with Triton-PSB buffer (2% v/v Triton-X-100 in PSB), using a CytoTox
96R Non-Radioactive Cytotoxicity Assay (Promega Corporation, Madison, WI). Absorbance was
measured at 490nm using a UV/Vis spectrophotometer (Bio-Tek Instruments Inc.,Winooski, VT). A
calibration curve was constructed with a known number of platelets, counted using a Beckman
Coulter Z2 Particle Count and Size Analyzer (Beckman Coulter, Fullerton, CA), and the platelet
adhesion on the HSA films was determined using the calibration curve.
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4.2.13 Effect of flow shear on treated ePTFE
A custom-made and validated vascular simulator (Figure 4.3) was used to characterize the effect of
combined cyclic strain and flow shear on treated ePTFE [82]. For each experimental simulation,
6mm diameter silicone membranes were cut from biomedical grade silicone sheets (SMI, 0.15” NRV
G/G 40D, SMI, MI). The silicone membranes were cleaned as described above and steam sterilized
in an autoclave at 121°C for 1 hour. A sandwich was formed using sterile station rings and silicone
membrane. The simulator accommodates three such assemblies on each base plate (three loading
stations per base plate) providing a total sample size of 6 using 2 baseplates. The baseplates were
UV-sterilized for 12 hours followed by attachment of albumin coated and uncoated ePTFE grafts
using an epoxy resin (Devcon, MSC part # 00261115). Sterile Teflon rings (2.75 cm2 inner crosssectional area and 1.2 cm height) were centered on the ePTFE grafts on the silicone membrane above
the loading post.

Figure 4.3: Schematic for placement of ePTFE disc on the simulator base plate for assessment of
cellular response.
4.2.14 Smooth muscle cell culture and characterization
Using a protocol approved by Clemson University Institutional Animal Care and Use Committee,
abdominal aortas were harvested from 6-10 week old female Sprague-Dawley rats. Adventitial fat
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layers and endothelium were removed. VSMCs were isolated from the vascular medium using
collagenase type II (Worthington, Biomedical, Lakewood, NJ) and elastase (Worthington
Biomedical, Lakewood, NJ) [64]. The cells were maintained in Dulbecco’s modification of Eagle
Medium (DMEM, 10-013-CV; Mediumtech, Herndon, VA) supplemented with 10% heatinactivated fetal bovine serum (FBS) (F-4135; Sigma-Aldrich, St. Louis, MO) and 1% antibioticantimycotic (A5955, Sigma-Aldrich, St. Louis, MO) under standard cell culture conditions (37°C,
5%CO2, 95% relative humidity).
Experiments were carried out using VSMCs between passages 4 to 8. For experimental testing, cells
were trypsinized using 0.25% trypsin containing 0.2mg/mL EDTA (Sigma Chemical Company,
E6511, St. Louis, MO, USA).
Smooth muscle cells were characterized by immunofluorescent staining for contractile marker
smooth muscle α-actin (SM α-actin). VSMCs were fixed with cold 4% formaldehyde and blocked
for 45 minutes at room temperature with a blocking solution that consisted of 40mg/ml bovine serum
albumin in PBS, 6% FBS, and 0.05% Triton-X. Cells were then treated with primary mouse anti-αactin antibody (ab5694, Abcam) diluted 1:500 overnight at 4°C. Cells were then treated with
fluorescent tagged goat anti-mouse secondary antibody and goat anti-rabbit secondary antibody, both
diluted 1:200 in the blocking solution, for 3 hours respectively at room temperature. The cells were
then stained with DAPI (Molecular Probes, D-1306, Eugene, OR) and imaged using fluorescent
microscopy (Nikon LV-UDM, Nikon Instruments Inc., Melville, NY).
Experimental groups consisted of albumin coated (15mm diameter; N=6) and uncoated ePTFE discs
(15mm diameter; N=6). The cells were maintained in Dulbecco’s modification of Eagle Medium
(DMEM, 10-013-CV; Mediumtech, Herndon, VA) supplemented with 10% heat-inactivated fetal
bovine serum (FBS) (F-4135; Sigma-Aldrich, St. Louis, MO) and 1% antibiotic-antimycotic (A5955,
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Sigma-Aldrich, St. Louis, MO) under standard cell culture conditions (37C, 5%CO2, 95% relative
humidity) and subjected to forces of cyclic strain of 0-7% and flow shear of 0.2-0.5 dynes/cm2 with
a flow rate of 225mL/min for 7 days.
4.2.14.1 Effect of epoxy glue treatment
In order to determine cellular response to the epoxy glue used to affix the ePTFE specimens to the
silicone membrane in the vascular simulator, vascular smooth muscle cells between passages 4-8
were cultured on 250 µL of epoxy glue (Devcon, Danvers, MA) and non-epoxy treated polystyrene
culture wells for assessment of cell proliferation over periods of 7 and 15 days.
4.2.14.2 Co-culture of platelets and smooth muscle cells
Vascular smooth muscle cells were cultured and allowed to adhere to albumin coated and bare ePTFE
discs for 72 hours. Platelet rich plasma (PRP) isolated from fresh human blood was incubated on
adhered vascular smooth muscle cells for 12 hours. Platelet supplemented smooth muscle cells on
ePTFE were subjected to application of forces of cyclic strain of 0-7% and flow shear of 0.2-0.5
dynes/cm2 with a flow rate of 225mL/min for 7 days; cells were evaluated using the test methods
described below.

4.2.14.3 Cell Morphology
After 7 days of culture, cells were fixed in 4% paraformaldehyde solution for 20 minutes and
permeabilized using 0.25% Triton-X detergent in phosphate buffer for 10 minutes. The cytoskeletal
F-actin and cell nuclei were stained using 25 μg/ml rhodamine-phalloidin (Invitrogen, R415) and 2(4-amidinophenyl)-1H -indole-6-carboxamidine (DAPI) (Molecular Probes, D-1306, Eugene, OR)
respectively. The cells were then imaged using fluorescent microscopy (Nikon Inc., Diaphot 30).
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4.2.14.4 Cell proliferation
VSMC proliferation was analyzed by assessing the reduction of methylthiazole tetrazolium (MTT)
(Sigma-Aldrich,

MO,

USA)

dye

after

24

hours.

3-(4,5-dimethylthiazol

-2-YL)-2,5-

diphenyltetrazolium bromide salt was dissolved in 1x DPBS at a concentration of 2mg/mL. VSMCs
were rinsed with 1x DPBS and then placed in 1mL DMEM solution with no FBS. A total of 240 μl
of MTT was added to the well, and the solution was incubated for 4 hours. After incubation, the
MTT-DMEM solution was removed and 1mL of DMSO was added to the well. Using a plate reader,
absorbance was then read at 570nm.
4.2.14.5 Expression of SMC alpha-actin
α-actin expression in smooth muscle cells cultured on albumin coated and uncoated ePTFE grafts
was analyzed using a modified cell-based ELISA assay [83]. Briefly, at indicated times, the medium
was removed, and the cells were fixed in cold methanol. They were then incubated with a blocking
solution that consisted of 40mg/ml bovine serum albumin in PBS, 6% FBS, and 0.05% Triton-X for
45 minutes at room temperature. Primary mouse anti-α-actin antibody diluted 1:200 in the blocking
solution was then added to the discs for 2 hours at room temperature followed by a 2 hr treatment
with biotin conjugated bovine anti-mouse IgG, also diluted 1:200 in the blocking solution. After
extensive washing, the cells were incubated with horseradish peroxidase (HRP) conjugated antimouse secondary antibody. Chromogenic substrate (3 mM p-nitrophenyl phosphate, 0.05 M
Na2CO3, and 0.05 mM MgCl2) was then applied to produce color, and the absorbance was read at
405 nm with a microplate reader (Beckman Instruments, Inc., Model #DU®640B, Fullerton, CA)
normalized against cell count on each disc giving a number directly related to the α-actin content per
cell. The cells were then DAPI stained and imaged to facilitate cell counting.
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4.2.15 In-vitro Flow Loop circulation model
A flow experiment was designed for albumin coated ePTFE small diameter grafts to assess the
adhesion of bovine platelets to the albumin coated and bare ePTFE grafts (Figure 4.4). A flow rate
of 225mL/min was employed to simulate the physiological relevant low flow conditions. Silicone
tubes were connected to the ePTFE graft using brass connectors. The tubing and graft were
connected to a pulsatile pump to provide the required flow rate. A closed loop system was designed
to allow fabrication of albumin film and assessment of response of fluorescently labeled fibrinogen
and platelet-rich plasma to the albumin coated ePTFE grafts under controllable hemodynamic
conditions.

Figure 4.4: Setup of the flow loop circulation model.
4.2.16 Fabrication of albumin film coated small diameter ePTFE tube: ePTFE tubes of 3mm
inner diameter and 4mm thickness (Aeos™ ePTFE; Extruded Sub-Lite-Wall®; 0.096+/-.003 ID,
Zeus, Orangeburg, SC) were plasma treated before functionalization with surface active hydroxyl,
carbonyl, carboxyl and nitroxide groups. Surface activated ePTFE tubes were modified with 0.5%
wt/vol PGMA (Mn =176000 g/mol) in chloroform to produce an epoxy-rich anchoring layer
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followed by 5% wt/vol HSA solution by circulation of PGMA and HSA solution with a flow rate
of 225mL/min. HSA coated tubes were then annealed at 150 ̊C in a vacuum oven for 1 hour [34]
followed by ethylene oxide sterilization by ISO-11135-2014 [35].
4.2.17 Fourier-transform Infrared (FT-IR) Attenuated Total Reflectance (ATR) spectroscopy:
The binding between PGMA and HSA was confirmed by ATR-FTIR spectroscopy. FTIR-ATR
spectroscopy was performed using a Nicolet SX-60 FTIR spectrometer to collect IR spectra for
albumin, PGMA and albumin-PGMA coated ePTFE graft cut open and inner surface pressed on a
diamond crystal stage surface pressed on a diamond crystal stage. Absorption spectra over the range
400-4000cm-1 was collected at a resolution of 8 with 128 scans using OMNIC software.

4.2.18 Scanning Electron Microscopy (SEM): Scanning electron microscopy was done to visualize
the morphology of albumin coated and bare ePTFE surface. Prior to imaging, the grafts were cut
open and coated with a 10nm layer of platinum. A scanning electron microscope model SU-6600
with accelerating voltage of 5.0kV and working distance 10.6mm was used to obtain images at 250x,
500x and 1000x.

4.2.19 Energy dispersive X-ray spectroscopy (EDX): Electron dispersive x-rays (EDS, Model S3400N, Hitachi, Japan) were used to gain a quantitative breakdown of elements on the albumin
coated and uncoated surfaces.
4.2.20 Human Fibrinogen adsorption: Human fibrinogen (FIB-3; plasminogen, von Willebrand
factor, and fibronectin depleted; Enzyme Research Laboratories, South Bend, IN) was
fluorescently labeled using the protocol described in section 2.11 and circulated through the
albumin coated and uncoated ePTFE tubes (n=4) for 1 hour followed by measurement of
fluorescence at excitation-emission wavelengths of 575 and 525nm.
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4.2.21 Bovine Platelet Isolation and adhesion
Heparin-anticoagulated fresh porcine blood was centrifuged (225g, 15 min, 25C) to obtain plateletrich plasma using a Beckman Coulter Allegra 6R centrifuge. A platelet concentration of 106
platelets/mL in platelet suspension buffer (137mM NaCl, 2.7mM KCl, 5.5mM Dextrose, 0.4 mM
sodium phosphate monobasic, 10 mM HEPES and 0.1U/ml apyrase) was used. Platelet suspension
buffer was added with 2.5 mM CaCl2 and 1.0mM MgCl2 to activate the platelets.
The platelet-rich plasma solution was allowed to rest for 30 minutes at 37°C before being circulated
through the HSA coated ePTFE and the uncoated ePTFE tubes (n=4) with a flow rate of 225mL/min
for 24 hours in an incubator at 37°C, 5%CO2, 95% relative humidity. At the end of the 24 hour
incubation period, the grafts were rinsed with phosphate buffer to remove unbound platelets. Platelet
adhesion was assessed using the protocol described in section 4.2.12.
4.2.22. Statistical Analysis
The statistical significance of differences between mean values reported with 95% confidence
intervals (CI) for different samples and conditions was assessed using a student’s t-test, with p-value
≤ 0.05 as significant.

4.3 Results
4.3.1 Attenuated Total Reflectance (ATR) Fourier-transform Infrared (FT-IR) spectroscopy:
ATR-FTIR spectroscopy confirmed the presence of human albumin and PGMA on ePTFE.
Wavenumbers of amide I (1655cm-1) and amide II (1541cm-1) bonds depict stability of the alphahelical secondary structural conformation of human albumin on the ePTFE surface (Figure 4.5).
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a)

b)

c)
Figure 4.5: IR spectra of a) human serum albumin, b) poly (glycidyl methacrylate) (PGMA) and
c) IR spectra of human serum albumin bound to poly(glycidyl methacrylate)(PGMA) on ePTFE
surface with characteristic amide I (1655cm-1) and amide II (1541cm-1) bands and carbonyl band
(1725cm-1).

4.3.2 Fluorescent labeling of albumin: Presence of fluorescently labeled albumin on ePTFE
surface under physiological conditions of flow shear (phosphate buffer, pH 7.4, 37°C) for a period
of 30 days confirmed the strong binding strength of albumin to the surface (Figure 4.6).
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Day 1

Day 15

Day 30

Figure 4.6: Images of fluorescently labeled albumin on ePTFE surface assessed for up to 30 days.

4.3.3 Tensile strength of albumin film: Albumin coating on ePTFE surface does not cause a
significant change in the tensile strength of ePTFE in dry- or fluid-state conditions after application
of longitudinal tensile force (Figure 4.8); thus, the ePTFE surface retains its mechanical strength to
withstand stresses during flow shear. Presence of albumin before and after tensile application by IR
spectroscopy indicates strong binding to the surface (Figure 4.7).

Figure 4.7: Measurements of tensile strength of albumin coated ePTFE and bare ePTFE in dry- and
fluid-state conditions. Data represented as mean ± standard deviation.

Values represented as Mean ± SD (error bar) with n=6 for each sample.
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a)

b)

Figure 4.8: IR spectra of human serum albumin bound to poly(glycidyl methacrylate)(PGMA) on
ePTFE surface a) before and b) after tensile force application.

4.3.4 Scanning Electron Microscopy (SEM) and Energy Dispersive Spectroscopy (EDX).
SEM-EDX analysis revealed the presence of a nitrogen element, signifying the presence of
albumin after application of tensile force (Figure 4.9 and 4.10) indicating a strong binding strength
of albumin film on ePTFE surface in dry and physiological fluid state conditions (phosphate buffer,
37°C, pH 7.4).

a)

b)

Figure 4.9: SEM images of albumin coated ePTFE surface after application of tensile force in a)
dry and b) fluid state at 1000x magnification.
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Spectrum

C (wt%)

F (wt%)

N (wt%) Spectrum

C (wt%)

F (wt%)

N (wt%)

Spectrum 1

23.87

73.17

2.95

Spectrum 1

21.73

74.50

3.77

Spectrum 2

24.95

73.72

1.33

Spectrum 2

21.59

76.92

1.49

Spectrum 3

25.79

69.58

4.63

Spectrum 3

24.10

70.12

5.78

After tensile force in dry state

After tensile force in fluid state

Figure 4.10: Elemental composition of albumin coated ePTFE before and after application of
tensile force at 1000x magnification.

4.3.5 Surface Wettability: Human albumin significantly enhanced the surface wettability of the
ePTFE surface, as evidenced by measurement of a lower water contact angle of 78±3.7º on
albumin coated ePTFE as compared to 125±4.8º for uncoated ePTFE (Figure 4.11).

a)

b)

Surface

Contact angle

ePTFE

125±4.8

Albumin coated ePTFE

78±3.7

Figure 4.11: Measurement of surface wettability of albumin coated ePTFE and bare ePTFE by contact
angle analysis. Values represented as mean ± SD (error bar) with n=6 for each sample group.
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4.3.6 Smooth muscle cell culture
Cell proliferation measurements reveal controlled smooth muscle cell count on albumin coated
ePTFE compared to bare ePTFE assessed for a period of 7 days (Figure 4.12) under low flow shear
stress conditions of 0.5 dynes/cm square. While no significant difference was observed in
proliferation of smooth muscle cells on albumin coated and bare ePTFE, SMCs co-cultured with
platelets were significantly fewer in count on albumin ePTFE compared with bare ePTFE. This was
revealed by reduction of MTT salt to a formazon product by active reductase enzymes, which
permitted quantification of metabolically active, healthy and proliferating cells (materials
cytotoxicity) via colorimetric measurements.

Figure 4.12: Measurement of smooth muscle cell proliferation on albumin coated and bare e-PTFE.
Values represented as mean ± SD (error bar) with n=6 for each sample.

Morphology (Figure 4.13) and aspect ratio (Figure 4.14) measurement of smooth muscle cells
cultured on albumin coated and bare ePTFE reveal a spindle shaped and contractile morphology on
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albumin coated ePTFE as compared to bare ePTFE, evidenced by fluorescent staining with
rhodamine-phalloidin and DAPI.
SMC

Platelet-SMC

HSA-e-PTFE

e-PTFE

Figure 4.13: Morphology of smooth muscle cells cultured on albumin coated and bare e-PTFE. Values
represented as mean ± SD (error bar) with n=6 for each sample.
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Figure 4.14: Aspect ratio of smooth muscle cells cultured on albumin coated and bare e-PTFE. Values
represented as mean ± SD (error bar) with n=6 for each sample.

A significant difference (p=0.012) was observed in the expression of contractile marker smooth
muscle alpha actin on smooth muscle cells cultured on albumin coated ePTFE compared to bare
ePTFE (Figure 4.15).

Figure 4.15: Measurement of expression of contractile marker smooth muscle alpha-actin by smooth
muscle cells cultured on albumin coated and bare e-PTFE. Values represented as Mean ± SD (error bar)
with n=6 for each sample.
120

4.3.7 Fibrinogen adhesion force measurements: Adhesion force of human fibrinogen was
significantly less (p=0.01) to albumin coated ePTFE surface compared to bare ePTFE (Figure
4.16).

Figure 4.16: Measurement of adhesion force of fibrinogen to albumin coated ePTFE and bare ePTFE.
Values represented as mean ± SD (error bar) with n=6 for each sample.

4.3.9 Response of epoxy-treated smooth muscle cells
No significant difference (p=0.06) between the smooth muscle cell proliferation on epoxy treated
and untreated surface was measured (Figure 4.17).
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Figure 4.17: Measurement of smooth muscle cell proliferation on epoxy-treated and untreated ePTFE. Values represented as mean ± SD (error bar) with n=6 for each sample.
4.3.10 Fluorescent labeling of fibrinogen: As depicted in Figure 4.18, human albumin film
significantly reduced (p=0.03) the adsorption of human fibrinogen as compared to bare ePTFE
surface and silicone.

Figure 4.18: Measurement of adsorption of human fibrinogen on albumin coated ePTFE (161 ± 23ng/mm
square) and bare ePTFE (562 ± 34 ng/mm square). Polystyrene and silicone were used as positive
controls. Values represented as mean ± SD (error bar) with n=4 for each sample.
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4.3.11 Adhesion of Human Platelets: Human albumin significantly (p=0.023) reduces the
adhesion of human platelets as compared to bare the ePTFE surface (Figure 4.19).

Figure 4.19: Measurement of adhesion of human platelets on albumin coated ePTFE (11.2 ± 1%) and
bare e–PTFE (23 ± 2.1%). Polystyrene and silicone were used as positive controls. Values
represented as mean ± SD (error bar) with n=4 for each sample.

4.3.12 Albumin release quantification (Biodegradation): Long term stability of albumin on the
ePTFE surface is evident from the controlled degradation profile of albumin, indicating strong
binding strength. Strong binding strength of albumin to the ePTFE surface as evident from long
term stability promises a potential vascular coating (Figure 4.21).
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Figure 4.20: Degradation profile of human albumin from ePTFE.

4.3.13 Albumin binding strength
Strong binding strength of albumin on the ePTFE surface was assessed by ATR-FTIR analysis of
albumin coated ePTFE exposed to mechanical forces of flow shear for 20 days in phosphate buffer
(pH 7.4 and 37°C) in a vascular simulator [82].

a)

b)

Figure 4.21: Infrared spectra of albumin-coated ePTFE before a) and after b) application of flow shear for 20 days.
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4.3.14 Human Fibrinogen Adsorption
A significant difference in the adsorption of fluorescently labeled human fibrinogen was measured
on albumin coated and uncoated ePTFE graft.

Figure 4.22: Measurement of adsorption of human fibrinogen on albumin coated ePTFE and bare ePTFE.
Values represented as mean ± SD (error bar) with n=4 for each sample.

4.3.15 Platelet adhesion
As depicted in Figure 4. 23, albumin coated ePTFE (3.4±0.1%) allows significantly less adhesion
of bovine platelets compared to bare ePTFE graft (12.1±0.7%).
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Figure 4.23: Measurement of adhesion of human platelets on albumin coated ePTFE and bare
ePTFE. Values represented as mean ± SD (error bar) with n=4 for each sample.

4.4 Discussion
Designing surface modification strategies for mitigating the two major complications of vascular
grafts, thrombosis and intimal hyperplasia, is an extensive area of research. High hydrophobicity, a
major limitation of expanded-polytetrafluoroethylene (ePTFE), allows significant adsorption of
adhesive proteins and subsequently platelets facilitating incomplete healing increasing the propensity
of thrombosis and intimal hyperplasia [37-39].
HSA is the most abundant protein present in human blood and has been shown to passivate
material surfaces, thus blocking sites for adsorption of other proteins and adhesion of platelets and
cells by blocking surface active sites [22-29, 40-42]. Several techniques to fabricate an albumin
film on the ePTFE surface have been attempted using cross-linking agents such as carbodiimide
and glutaraldehyde [43-45]. However, none of the techniques has allowed long-term stability of
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albumin on the surface to for prolonged protection from platelet adhesion and hyperplasia of
smooth muscle cells.
In the proposed technology, we employed PGMA as an anchoring layer to covalently bind amine
groups in albumin to the ePTFE surface. The glycidyl methacrylate units located in the “loops” and
“tails” sections of the attached PGMA chain could serve as reactive sites for the subsequent
attachment of (macro) molecules with complementary functional groups [30-32]. PGMA is also
known for its high surface density and affinity for reacting with proteins [33].
Epoxy groups in PGMA act as reactive sites for attachment with functional groups on graft surfaces
and for immobilization of non-thrombogenic coatings such as albumin. Structural stability of
albumin has been shown to be critical to prevent adhesion of platelets. Lacking receptors for binding
platelets, albumin has been shown to attract platelets beyond a critical degree of unfolding when it
exposes its hydrophobic residues. Epoxy groups in PGMA render albumin in its native conformation,
thus preserving its secondary structure conformation, as shown in our previous study [46].
Characterization of albumin coated ePTFE was performed using attenuated total reflection-fourier
transform infrared spectroscopy (ATR-FTIR) for confirmation of binding of albumin to PGMA
bound ePTFE, energy dispersive spectroscopy (EDX) for chemical composition analysis and
scanning electron microscopy (SEM) for morphological analysis, contact angle analysis for
estimation of surface energy changes.
Binding between PGMA and albumin on the ePTFE surface was assessed by ATR-FTIR analysis.
Presence of a characteristic carbonyl group of PGMA (1723 cm-1) and amide I (1655 cm-1) and amide
II (1541 cm-1) bands of albumin confirms PGMA and albumin coating on the ePTFE surface.
Secondary structure confirmation of albumin bound to PGMA was assessed by the wavenumbers of
the amide I and amide II bands (1655 cm-1 and 1541 cm-1, respectively) correspond to the alpha-
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helical structural range, confirming the native secondary structure conformation of albumin on
PGMA polymer [47].
The degradation temperature of ePTFE was assessed by thermo-gravimetric analysis to assess
stability of the material at 150°C albumin coating annealing temperature. Insignificant mass loss of
ePTFE at 150°C for 1 hour confirms its stability at the annealing conditions.
Antithrombogenic activity of albumin was assessed by measuring fibrinogen adsorption, adhesion
force and human platelet adhesion on albumin coated ePTFE surfaces. Fibrinogen is known to be
critical in attracting platelets and subsequently facilitating thrombus formation [48,49]. There was a
significant decrease in the adsorption of fluorescently human fibrinogen on the albumin coated
ePTFE surface under flow. Adhesion force between human fibrinogen and the albumin surface was
significantly low as compared to bare ePTFE surface assessed by AFM colloidal probe microscopy.
Albumin coated ePTFE surface significantly reduced the adhesion of platelets assessed by LDH
activity for a period of 7 days under physiologically relevant low flow shear stress conditions of 0.5
dynes/cm2. These results are promising as compared to attempts to bind albumin on Dacron surfaces
using crosslinking agents, which have been able to provide only short-term stability and protection
to platelets [43-45]. Hydrophilic surfaces have been shown to improve biocompatibility, providing
platelet adhesion and activation [50]. With a contact angle of >125, ePTFE is highly hydrophobic.
Albumin coating significantly enhances the surface wettability (θ=78±2.3) of the ePTFE vascular
graft surface as assessed by contact angle analysis.
Vascular smooth muscle cells play a critical role in facilitating the progression of anastomotic
hyperplasia. Smooth muscle cell proliferation, hypertrophy and expression of contractile expression
marker smooth muscle alpha actin were studied to assess the potential of albumin film on mitigation
of intimal hyperplasia. Injury due to a percutaneous coronary interventional procedure (PCI) causes
endothelial denudation, exposing smooth muscle cells to growth factors, which promotes the
128

phenotypic shift in the morphology of smooth muscle cells from contractile to synthetic with
increased proliferation and migration from medial layer to neo-intimal layer and increased
extracellular matrix formation [55]. Phenotypic modulation has been considered to be a key factor
responsible for progression of neo-intimal hyperplasia and restenosis. Hemodynamic factors such as
wall shear stress and cyclic strain from blood flow modulate the phenotype and function of vascular
smooth muscle cells [56]. Physiological levels of cyclic strain promote quiescent, contractile
morphology of smooth muscle cells, [57] whereas high rates promote SMC proliferation and
dedifferentiation [58-60]. Endothelial denudation or VSMC migration causes exposure of the latter
to blood flow [56]. Shear stress is known to cause a direct effect on smooth muscle cell proliferation
with physiological shear stress reducing proliferation and maintaining contractile morphology [6162] and low shear stress conditions especially in small diameter blood vessels and grafts promoting
smooth muscle cell proliferation and synthetic phenotype [63] and with up-regulation of growth
factors such as PDGF [64]. In vivo and clinical studies have demonstrated the occurrence of thicker
neo-intima under low wall shear stress [65-66].
In vitro systems have been designed to evaluate cellular response to altered shear stress. Shun et al.
designed a parallel flow chamber designed to culture cells on a glass slide sandwiched between
polycarbonate plates [67] with a small gap between the plates allowing circulation of cell culture
medium. A cone and plate system with the cone rotating at an angular velocity is another system
designed. For small angles, the shear rate (shear stress) is constant throughout the flow field [67].
However, none of the models has been able to concurrently provide the cyclic strain and flow shear
stress forces to accurately assess the effect of smooth muscle cells for developing effective antirestenotic therapies.
In this study, we employed a custom designed vascular simulator [68] to provide the physiologically
relevant conditions of cyclic strain and low flow shear to assess the response of vascular smooth
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muscle cells at the site of a bypass graft anastomosis. The simulator provided a parallel plate flow
chamber with a computer-controlled vacuum pressure to strain a silicone membrane fixed on a
stationary post to provide forces of cyclic strain and flow shear. Studies highlighting the effect of
fluid shear and cyclic strain on endothelial cells have been shown [69]; little study has been given to
the effect of the forces on smooth muscle cells. Acampora et. al. studied the combined effect of strain
and fluid shear (4% and 0.5 dynes/ cm2, respectively) and reported a 75% increase in smooth muscle
cell proliferation and a 19% decrease in alpha-actin expression [82]. We studied the response of
smooth muscle cells on albumin coated and uncoated ePTFE surfaces exposed to forces of cyclic
strain and flow shear using the vascular simulator. Smooth muscle cells on albumin coated ePTFE
showed a significant decrease in proliferation and a hypertrophic response as compared to bare
ePTFE. A significant increase in the expression of smooth muscle alpha actin protein was measured
in smooth muscle cells cultured on albumin coated ePTFE compared to bare ePTFE.
After intimal injury, cells such as platelets and inflammatory cells release growth factors and
cytokines that cause accelerated migration and proliferation of VSMCs from media to intima and a
phenotypic change from a contractile to a synthetic state [81]. In this study, a co-culture of platelets
and smooth muscle cells was studied to assess the potential of albumin film to reduce intimal
hyperplasia in the presence of growth factors released from platelets. Smooth muscle cells on
albumin coated ePTFE conditioned with and without platelets and subjected to physiologically
relevant mechanical forces of cyclic strain and flow shear for 7 days were found to have significantly
less proliferation and increased expression of contractile marker smooth muscle alpha actin than
uncoated ePTFE.
In vitro models employed to facilitate perfusion of blood through polymeric conduits have analyzed
many physiological endpoint-associated with blood contacting surfaces. Slee et. al. designed an ex
vivo chandler loop apparatus to assess blood and cell interactions to recCD47 bound polyurethane
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tubing [68-69]. However, the major disadvantage of these systems have been the requirement to
include air in the tube, which might cause leukocyte and platelet aggregation and protein
denaturation, [70-72] interfering with physiological end points. Also, air remains at the highest point
of the circuit, limiting the blood circulation rate [73]. The perfusion model used in this study to assess
the response of fibrinogen adsorption and platelet adhesion to albumin-coated 2.4mm diameter and
10cm long ePTFE tubes allowed full contact with fluid. Adhesion of bovine platelets under perfusion
flow on albumin coated ePTFE was lower than bare ePTFE grafts. This is consistent with the data
obtained for adhesion of platelets under conditions of flow shear in an orbital shaker. These results
are in agreement with low platelet adhesion measurements on albumin coated Dacron grafts gathered
by Kottke-Marchantand collaborators in vitro [43]. While albumin has been shown to prevent
adhesion of platelets, adhesive protein fibrinogen has been proved to play a key role in facilitating
adhesion of platelets to biomaterial surfaces [74-77]. In our flow model, we observed significantly
lower adsorption of fluorescently labeled fibrinogen on albumin coated ePTFE compared to uncoated
ePTFE evidenced by fluorescence values obtained at 525nm excitation and 575nm emission
wavelengths.
Adhesion strength of a vascular coating is crucial to provide long term blood-biocompatibility and
graft patency. Albumin coating on Dacron grafts using glutaraldehyde as a cross-linking agent has
shown short term stability for only 7-10 days [78-80]. We studied strong binding of albumin on
ePTFE surface bound to a PGMA anchoring layer over a 45 day period in vitro under physiological
conditions with no significant change in the albumin surface density with time. Binding strength of
the albumin film was also assessed by application of longitudinal tensile force to the coated and bare
ePTFE surface. There was no significant change in the adhesion strength of the ePTFE material after
albumin coating. Confirmation of albumin film on the node-fibril structure of ePTFE was assessed
by energy dispersive x-ray (EDX) spectroscopy for chemical analysis of nitrogen element in amine
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groups of albumin after application of longitudinal tensile force. We showed that albumin on ePTFE
surface can be coated without any change in mechanical properties or node-fibril microstructure.

4.5 Conclusions:
It is expected that the results of this study will be relevant in understanding albumin as a potential
coating with strong binding strength to prevent the complications of thrombosis and intimal
hyperplasia. Moreover, data from this research could be used by endovascular device manufacturers
for development of biocompatible vascular grafts and the appropriate testing protocols for assessing
their efficacy. Assessment of the effect of albumin film on mitigation of thrombogenicity and
neointimal hyperplasia in an in vivo model would be the focus of future work.
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CHAPTER 5

CONCLUSIONS AND RECOMMENDATIONS

CONCLUSIONS
A technique to create a human albumin film on metallic and polymeric materials was designed using
poly-glycidyl methacrylate as an anchoring layer to mitigate the complications of thrombogenicity
and intimal hyperplasia. Human albumin film was characterized by FT-IR spectroscopy, scanning
electron microscopy, energy dispersive x-ray spectroscopy, atomic force microscopy and contact
angle analysis. Potential of albumin film to mitigate thrombogenicity was assessed by measurement
of human fibrinogen adsorption and human and bovine platelet adhesion. Response of vascular
smooth muscle cells on albumin film was assessed by measurement of proliferation, morphology,
cell aspect ratio and contractile protein marker smooth muscle alpha-actin. Several conclusions can
be drawn from this doctoral research.

1. Human albumin film exhibits strong adhesion strength to metallic and polymeric substrates
using PGMA as an anchoring layer.
2. Human albumin film shields the surface from adsorption of human fibrinogen which plays
a key role in facilitating the adhesion and aggregation of platelets on a surface.
3. Human albumin film prevents the adhesion of human and bovine platelet adhesion on the
surface thereby conferring anti-thrombogenicity to metallic and polymeric materials.
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4. Vascular smooth muscle cells maintain a controlled proliferation profile, spindle shape
morphology and increased expression of smooth muscle alpha-actin on albumin coated
surfaces thereby mitigating complications of intimal hyperplasia.
Results how that human albumin film on metallic and polymeric surfaces can shield the adsorption
and adhesion of mediators facilitating the formation of a thrombus and restenosis. This research,
therefore, demonstrated the potential of a human albumin film on a PGMA anchoring layer to
mitigate the complications of thrombogenicity and intimal hyperplasia.

RECOMMENDATIONS

1. In vivo model: An animal model could be the next step for this research to study the effect
of albumin film to enhance hemocompatibility in terms of reducing adhesion of platelets and
fibrin formation on the luminal surface of a synthetic graft. The animal model will simulate
the exact flow shear conditions in a low diameter graft in the presence of growth factors and
proteins present in the bloodstream. Parameters such as compliance mismatch, suturability
and dilatation could be studied accurately in an animal model for any required improvements
in the mechanical properties of the graft.

2. Effect of inflammation: Albumin film on stent and graft surface could be studied for its
potential to reduce inflammation in terms of modulating the response of macrophages and
complement system which cause adverse reactions post a stent implantation and a bypass
surgery in terms of secretion of growth factors to facilitate proliferation of vascular smooth
muscle cells.
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3. Efficacy to promote endothelial growth: Endothelial healing of a vascular graft is essential
to protect the luminal surface from platelet adhesion and hyperplasia of smooth muscle cells
as endothelial cells release factors such as nitric oxide (NO), prostacyclin (PGI2) and heparin
sulfate to inhibit the growth of smooth muscle cells and prevent platelet activation and
deposition for homeostasis and maintenance of vascular integrity.

4. Drug delivery: Release of drugs or growth factors for promoting endothelial cell healing or
anti-platelet molecules could be facilitated using the human albumin film for further
improving its potential to promote healing in a vessel or synthetic conduit post surgery.

5. A potential coating for diverse applications: Human albumin film could be used for other
vascular or non-vascular applications such as pacemakers, heart valves, ventricular assist
devices, catheters, guide wire for its efficacy to be biocompatible and blood-compatible and
for coatings featuring slow degrading drug release profile such as orthopaedic implants,
sutures and meshes.

6. Anti-bacterial film: Human albumin has been known to have anti-bacterial properties
enhancing its applications in a diverse array of fields. To validate its efficacy as anti-bacterial
film could be tested in in vitro and in vivo models.
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